Cardax (CDXI) 10-K 15 Apr 21 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2020	Mar. 30, 2021	Jun. 30, 2020
Cover [Abstract]
Entity Registrant Name	CARDAX, INC.
Entity Central Index Key	0001544238
Document Type	10-K
Document Period End Date	Dec. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filer	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 1,565,064
Entity Common Stock, Shares Outstanding		794,183
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2020

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
CURRENT ASSETS
Cash	$ 19,179	$ 19,303
Accounts receivable, net		205,768
Inventories	994,319	1,177,831
Deposits and other assets	3,063	2,066
Prepaid expenses	105,238	181,093
Total current assets	1,121,799	1,586,061
INTANGIBLE ASSETS, net	302,411	420,373
RIGHT TO USE LEASED ASSETS	962	12,488
TOTAL ASSETS	1,425,172	2,018,922
CURRENT LIABILITIES
Accrued payroll and payroll related expenses, current portion	4,362,381	3,687,376
Accounts payable and accrued expenses	1,689,352	1,544,402
Fees payable to directors	418,546	418,546
Accrued separation costs, current portion	12,000	9,000
Current portion of related party notes payable	769,000	575,000
Current portion of note payable	211,300
Related party convertible notes payable, net of discount	1,334,296	651,721
Convertible notes payable, net of discount	1,468,531	358,289
Employee settlement	50,000	50,000
Lease liability, current portion	962	11,527
Derivative liability on convertible notes payable	235,165	827,314
Total current liabilities	10,551,533	8,133,175
NON-CURRENT LIABILITIES
Note payable, less of current portion
Related party notes payable, less of current portion	1,000,000	1,000,000
Accrued separation costs, less current portion	71,635	83,635
Lease liability, less current portion		961
Total non-current liabilities	1,071,635	1,084,596
COMMITMENTS AND CONTINGENCIES
Total liabilities	11,623,168	9,217,771
STOCKHOLDERS' DEFICIT
Preferred Stock - $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding as of December 31, 2020, and December 31, 2019, respectively
Common stock - $0.001 par value; 400,000,000 shares authorized, 794,183 and 687,564 shares issued and outstanding as of December 31, 2020, and December 31, 2019, respectively	794	688
Additional paid-in-capital	61,893,072	59,836,818
Accumulated deficit	(72,091,862)	(67,036,355)
Total stockholders' deficit	(10,197,996)	(7,198,849)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 1,425,172	$ 2,018,922

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	400,000,000	400,000,000
Common stock, shares issued	794,183	687,564
Common stock, shares outstanding	794,183	687,564

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
REVENUES, net	$ 538,946	$ 710,949
COST OF GOODS SOLD	196,130	345,393
GROSS PROFIT	342,816	365,556
OPERATING EXPENSES:
Salaries and wages	1,419,070	1,552,226
Professional fees	575,175	920,208
Selling, general, and administrative expenses	607,408	906,074
Stock based compensation	632,500	708,588
Research and development	136,780	315,994
Depreciation and amortization	34,519	39,569
Total operating expenses	3,405,452	4,442,659
Loss from operations	(3,062,636)	(4,077,103)
OTHER INCOME (EXPENSE):
Change in fair value of derivative liability	222,707	(356,314)
Gain on modification of debt instruments	394,924
Other income	30,000
Loss on abandonment of patents	(98,056)	(36,205)
Loss on abandonment of pending stock issuance	(157,811)
Interest expense	(2,384,635)	(623,415)
Total other (expense) income, net	(1,992,871)	(1,015,934)
Loss before the provision for income taxes	(5,055,507)	(5,093,037)
PROVISION FOR INCOME TAXES
NET LOSS	$ (5,055,507)	$ (5,093,037)
NET LOSS PER SHARE
Basic	$ (6.79)	$ (7.49)
Diluted	$ (6.79)	$ (7.49)
SHARES USED IN CALCULATION OF NET LOSS PER SHARE
Basic	744,555	680,152
Diluted	744,555	680,152

Consolidated Statement of Chang

Consolidated Statement of Changes in Stockholders' Deficit - USD ($)	Common Stock [Member]	Additional Paid-In-Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2018	$ 670	$ 58,407,257	$ (61,943,318)	$ (3,535,391)
Balance, shares at Dec. 31, 2018	669,967
Common stock grants to independent directors	$ 11	349,989		350,000
Common stock grants to independent directors, shares	11,054
Common stock grants to service providers	$ 1	16,649		16,650
Common stock grants to service providers, shares	750
Stock based compensation - options		341,938		341,938
Restricted stock issuances	$ 8	244,992		245,000
Restricted stock issuances, shares	8,169
Issuance of warrants attached to convertible notes		125,545		125,545
Beneficial conversion feature issued on convertible notes		350,446		350,446
Retirement of issued stock	$ (2)	$ 2
Retirement of issued stock, shares	(2,376)
Net loss			$ (5,093,037)	$ (5,093,037)
Balance at Dec. 31, 2019	$ 688	59,836,818	(67,036,355)	(7,198,849)
Balance, shares at Dec. 31, 2019	687,564
Common stock grants to independent directors	$ 29	74,971		75,000
Common stock grants to independent directors, shares	28,737
Warrants granted to independent directors		300,000		300,000
Stock based compensation - options		257,500		257,500
Common stock grants to convertible note holders	$ 81	532,131		532,212
Common stock grants to convertible note holders, shares	81,409
Issuance of shares upon conversion of convertible note	$ 18	89,982		90,000
Issuance of shares upon conversion of convertible note, shares	18,000
Issuance of warrants attached to convertible notes		448,279		448,279
Beneficial conversion feature issued on convertible notes		141,390		141,390
Retirement of issued stock	$ (28)	$ 28
Retirement of issued stock, shares	(27,777)
Revaluation of notes payable discounts due to modification of conversion price		$ (271,998)		$ (271,998)
Extension fee for convertible note	$ 6	24,994		25,000
Extension fee for convertible note, shares	6,250
Extinguishment of derivative liability upon repayment of convertible note		458,977		458,977
Net loss			(5,055,507)	(5,055,507)
Balance at Dec. 31, 2020	$ 794	$ 61,893,072	$ (72,091,862)	$ (10,197,996)
Balance, shares at Dec. 31, 2020	794,183

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (5,055,507)	$ (5,093,037)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	34,519	39,569
Amortization of debt discount	1,841,388	417,001
Stock based compensation	632,500	708,588
Bad debt expense on note receivable and accrued interest	69,934
Loss on abandonment of patents	98,056	36,205
Loss on abandonment of pending stock issuance	157,811
Change in fair value of derivative liability	(222,707)	356,314
Gain on modification of debt instruments	(394,924)
Changes in assets and liabilities:
Accounts receivable	100,998	(138,258)
Inventories	183,512	302,549
Deposits and other assets	(997)	117,000
Prepaid expenses	(81,956)	(157,010)
Accrued payroll and payroll related expenses	675,005	259,365
Accounts payable and accrued expenses	179,785	(362,123)
Accrued separation costs	(9,000)	(9,000)
Net cash used in operating activities	(1,791,583)	(3,522,837)
CASH FLOWS FROM INVESTING ACTIVITIES:
Increase in intangible assets	(14,613)	(61,613)
Net cash used in investing activities	(14,613)	(61,613)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from the issuance of related party notes payable	219,000	1,575,000
Proceeds from the issuance of notes payable	236,300
Proceeds from the issuance of related party convertible notes payable	340,000	1,050,000
Proceeds from the issuance of convertible notes payable	1,720,000	490,000
Repayment of principal on related party notes payable	(25,000)
Repayment of principal on notes payable	(25,000)
Repayment of principal on convertible notes payable	(529,228)
Payment of debt issuance costs	(40,000)
Payment of extension costs on convertible notes payable	(90,000)
Proceeds from the issuance of common stock		245,000
Net cash provided by financing activities	1,806,072	3,360,000
NET DECREASE IN CASH	(124)	(224,450)
BEGINNING OF THE YEAR	19,303	243,753
END OF THE YEAR	19,179	19,303
SUPPLEMENTAL DISCLOSURES:
Cash paid for interest	416,015	137,688
Cash paid for income taxes
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Settlement of receivables with payables	34,836	89,572
Right to use assets funded through leases	11,526	12,488
Retirement of issued stock	28	2
Discounts recognized on notes payable at issuance	1,146,881	946,991
Extinguishment of derivative liability upon repayment of convertible notes	458,977
Revaluation of notes payable discounts due to modification of conversion price	271,998
Conversion of convertible note into common stock	$ 90,000

Company Background

Company Background	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Company Background	NOTE 1 – COMPANY BACKGROUND The Company’s predecessor, Cardax Pharmaceuticals, Inc. (“Holdings”), was incorporated in the State of Delaware on March 23, 2006. Cardax, Inc. (the “Company”) (OTCQB:CDXI) is a biopharmaceutical company primarily focused on the development of pharmaceuticals for chronic diseases driven by inflammation. The Company also has a commercial business unit that markets dietary supplements for inflammatory health. CDX-101, the Company’s astaxanthin pharmaceutical candidate, is being developed for cardiovascular inflammation and dyslipidemia, with a target initial indication of severe hypertriglyceridemia. CDX-301, the Company’s zeaxanthin pharmaceutical candidate, is being developed for macular degeneration. The Company’s pharmaceutical candidates are currently in pre-clinical development, including the planning of IND enabling studies. ZanthoSyn® is a physician recommended astaxanthin dietary supplement for inflammatory health. The Company sells ZanthoSyn® primarily through wholesale and e-commerce channels. The safety and efficacy of the Company’s products have not been directly evaluated in clinical trials or confirmed by the FDA. Going concern matters The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying consolidated financial statements, the Company incurred net losses of $5,055,507 and $5,093,037 for the years ended December 31, 2020 and 2019, respectively. The Company has incurred losses since inception resulting in an accumulated deficit of $72,091,862 as of December 31, 2020, and has had negative cash flows from operating activities since inception. Management expects that its marketing program for ZanthoSyn® will continue to focus on outreach to physicians, healthcare professionals, retail personnel, and consumers, and anticipates further losses in the development of its consumer business. The Company also plans to advance the research and development of its pharmaceutical candidates and anticipates further losses in the development of its pharmaceutical business. The Company’s ability to access the capital markets is unknown during the coronavirus disease 2019 (“COVID-19”) pandemic, which may limit or prevent the funding of its operations and related obligations. As a result of these and other factors, management has determined there is substantial doubt about the Company’s ability to continue as a going concern. The Company needs to raise additional capital to carry out its business plan. During the year-ended December 31, 2020, the Company raised $2,515,300 in gross proceeds through the issuance of debt securities. The Company filed a registration statement on Form S-1 on August 14, 2019, as amended September 27, 2019, and November 22, 2019, for a proposed $15 million public offering of common stock and warrants. The Company continued to take actions to advance the proposed public offering in 2020, but due to COVID-19 related travel restrictions, financial market conditions, and other considerations, the public offering was not consummated. In March 2021, the Company requested withdrawal of the registration statement from the Commission. The Company launched a private placement of preferred stock for an aggregate amount of up to $10 million with an initial closing of $50,000 on January 11, 2021; however, there can be no assurance that additional closings will be consummated. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was signed into law. The CARES Act provides aid to small businesses through programs administered by the U.S. Small Business Administration (the “SBA”). The CARES Act established a Paycheck Protection Program (the “PPP”), under which certain small businesses are eligible for loans to fund payroll expenses, rent, and related costs. In April 2020, the Company received a PPP loan (see Note 7). In February 2021, the Company received a Second Draw PPP loan. Under the terms of the program, the loan amounts may be forgiven if certain terms and conditions are met. Management believes the PPP loans received by the Company will be eligible for forgiveness in accordance with the terms of the program. The Company’s continued ability to raise capital through future equity and debt securities issuances is unknown, especially during the COVID-19 pandemic. If the Company is unable to obtain adequate capital, the Company may be required to cease operations or substantially curtail its ongoing and planned commercial activities. The ability to successfully resolve these factors raises substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these uncertainties.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of presentation The consolidated financial statements have been consistently prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and include the accounts of Cardax, Inc., and its wholly owned subsidiary, Cardax Pharma, Inc., and its predecessor, Cardax Pharmaceuticals, Inc., which was merged with and into Cardax, Inc. All significant intercompany balances and transactions have been eliminated in consolidation. Use of estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and the accompanying notes. Estimates in these consolidated financial statements include asset valuations, estimates of future cash flows from and the economic useful lives of long-lived assets, valuations of derivative liabilities, warrants, beneficial conversion features, and stock compensation, certain accrued liabilities, income taxes and tax valuation allowances, and fair value estimates. Despite management’s intention to establish accurate estimates and reasonable assumptions, actual results could differ materially from these estimates and assumptions. Cash The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. The Company held no cash equivalents as of December 31, 2020 and 2019. The Company maintains cash deposit accounts at one financial institution. Accounts at this institution are insured by the Federal Deposit Insurance Corporation up to $250,000. The Company’s cash balance at times may exceed these limits. As of December 31, 2020 and 2019, the Company had $0 in excess of federally insured limits on deposit. Accounts receivable Accounts receivable, net, of $0 and $205,768 as of December 31, 2020 and 2019, respectively, consists of amounts due from sales of dietary supplements. It is the Company’s policy to provide for an allowance for doubtful collections based upon a review of outstanding receivables, historical collection information, and existing economic conditions. Normal receivables are due 60 days after the issuance of the invoice. Receivables past due more than 90 days are considered delinquent. Delinquent receivables are written off based on individual credit evaluation and specific circumstances of the customer. No allowance was deemed necessary as of December 31, 2020 and 2019, respectively. Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined using the average cost method. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Inventory costs include third party costs for finished goods. The Company utilizes contract manufacturers and receives inventory in finished form. When necessary, the Company provides a reserve against inventory for known or expected inventory obsolescence. The reserve is determined by specific review of inventory items for product age and quality that may affect salability. There were no reserves necessary for inventory as of December 31, 2020 and 2019. Notes payable The Company issued various notes payable to related and non-related parties. These notes payable included original issue discounts, detachable warrants, conversion features, beneficial conversion features, debt issuance costs, and modifications. ● Original issue discounts. Interest and Imputation of Interest ● Detachable warrants. Debt ● Conversion features Derivatives and Hedging; Embedded Derivatives ● Beneficial conversion features. Debt ● Debt issuance costs. Debt ● Debt modifications. Debt Modifications and Extinguishments Stock issuance costs Stock issuance costs related to financing are accounted for as a reduction in stock proceeds in accordance with ASC No. 340-10, Other Assets and Deferred Costs Revenue from contracts with customers In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606) Under ASC No. 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to preform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance, and verify that collection of substantially all consideration is probable. The Company recognizes revenues from its contracts with customers for its products through wholesale and e-commerce channels when goods and services have been identified, the payment terms agreed to, the contract has commercial substance, both parties have approved the contract, and it is probable that the Company will collect all substantial consideration. The following table presents our revenues disaggregated by revenue source and geographical location. Sales and usage-based taxes are included as a component of revenues for the years ended December 31: Geographical area Source 2020 2019 United States Nutraceuticals $ 528,574 $ 705,694 Hong Kong Nutraceuticals $ 10,372 $ 5,255 Sales discounts, rebates, promotional amounts to vendors, and returns and allowances are recorded as a reduction to sales in the period in which sales are recorded. The Company records shipping charges and sales tax gross in revenues and cost of goods sold. Sales discounts and other adjustments are recorded at the time of sale. Cost of goods sold Cost of goods sold is comprised of costs to manufacture or acquire products sold to customers, direct and indirect distribution costs, and other costs incurred in the sale of goods. Shipping and handling costs Shipping and handling costs are included in cost of goods sold. Shipping and handling costs were $11,310 and $19,999 for the years ended December 31, 2020 and 2019, respectively. Sales and use tax Revenues, as presented on the accompanying income statement, include taxes collected from customers and remitted to governmental authorities. Such taxes were $3,045 and $3,018 for the years ended December 31, 2020 and 2019, respectively. Research and development Research and development costs are expensed as incurred and consists primarily of manufacturing of products, third-party research, clinical studies, laboratory supplies, and scientific advisory boards. The focus of these costs is on the development of astaxanthin, zeaxanthin, and related compounds. For the years ended December 31, 2020 and 2019, research and development costs were $136,780 and $315,994, respectively. Advertising Advertising costs are expensed as incurred and are included as an element of sales and marketing costs in the accompanying consolidated statements of operations. For the years ended December 31, 2020 and 2019, advertising costs were $27,366 and $161,468, respectively. Income taxes The Company accounts for income taxes under an asset and liability approach. Deferred income taxes reflect the impact of temporary differences between assets and liabilities recognized for financial reporting purposes and the amounts recognized for income tax reporting purposes, net operating loss carryforwards, and other tax credits measured by applying currently enacted tax laws. When necessary, a valuation allowance is provided to reduce deferred tax assets to an amount that is more likely than not to be realized. The Company determines whether a tax position is more likely than not to be sustained upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The Company uses a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon tax authority examination, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. The Company files income tax returns in the United States (“U.S.”), Hawaii, California, New York, and New York City jurisdictions. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment to apply. The federal, state, and city income tax returns of the Company are subject to examination by the IRS, state, and city taxing authorities, generally for three years after they were filed. The Company did not recognize any tax liabilities for income taxes associated with unrecognized tax benefits as of December 31, 2020 and 2019. The Company’s policy is to include interest and penalties related to unrecognized tax benefits, if any, within the provision for income taxes in the consolidated statements of operations. Fair value measurements U.S. GAAP establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below: Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access. Level 2: Inputs to the valuation methodology include: ● Quoted prices for similar assets or liabilities in active markets; ● Quoted prices for identical or similar assets or liabilities in inactive markets; ● Inputs other than quoted prices that are observable for the asset or liability; and ● Inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability. Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement. The asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. Stock based compensation The Company accounts for stock-based compensation costs under the provisions of FASB’s Accounting Standards Codification ASC No. 718, Compensation—Stock Compensation Equity Reclassifications The Company has made certain reclassifications to conform its prior periods’ data to the current presentation. These reclassifications had no effect on the reported results of operations or cash flows. Basic and diluted net loss per share Basic earnings per common share is calculated by dividing net loss for the year by the weighted average number of common shares outstanding during the year. Diluted earnings per common share is calculated by dividing net loss for the year by the sum of the weighted average number of common shares outstanding during the year plus the number of potentially dilutive common shares (“dilutive securities”) that were outstanding during the year. Dilutive securities include options granted pursuant to the Company’s stock option plans, and warrants issued to non-employees. Potentially dilutive securities are excluded from the computation of earnings per share in periods in which a net loss is reported, as their effect would be antidilutive. Recently adopted accounting pronouncements In November 2019, the FASB issued ASU No. 2019-08, Compensation—Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606) Recently issued accounting pronouncements In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity In December 2019, the FASB Issued ASU No. 2019-12, Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the consolidated financial statements.

Inventories

Inventories	12 Months Ended
	Dec. 31, 2020
Inventory Disclosure [Abstract]
Inventories	NOTE 3 – INVENTORIES Inventories consist of the following as of December 31: 2020 2019 Raw materials $ 759,400 $ 763,800 Finished goods 234,919 414,031 Total inventories $ 994,319 $ 1,177,831 As of December 31, 2020 and 2019, all raw materials were held at the manufacturer’s facility for future production. Additionally, as of December 31, 2020 and 2019, $227,597 and $407,756, respectively, in finished goods were held at the manufacturer’s facility for shipment.

Intangible Assets, Net

Intangible Assets, Net	12 Months Ended
	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, Net	NOTE 4 – INTANGIBLE ASSETS, net Intangible assets, net, consists of the following as of December 31: 2020 2019 Patents $ 499,106 $ 614,003 Less accumulated amortization (256,742 ) (332,081 ) 242,364 281,922 Patents pending 60,047 138,451 Total intangible assets, net $ 302,411 $ 420,373 Patents are amortized straight-line over a period of fifteen years. Amortization expense was $34,519 and $39,569 for the years ended December 31, 2020 and 2019, respectively. The Company has capitalized costs for several patents that are still pending. In those instances, the Company has not recorded any amortization. The Company will commence amortization when these patents are approved. The Company has 28 issued patents, including 13 in the U.S. and 15 outside the U.S. that will expire between 2023 and 2028, subject to patent term extensions. The Company also has four additional patents pending that if issued would extend patent coverage in the U.S. and outside the U.S. to 2039-2041.

Accrued Separation Costs

Accrued Separation Costs	12 Months Ended
	Dec. 31, 2020
Payables and Accruals [Abstract]
Accrued Separation Costs	NOTE 5 – ACCRUED SEPARATION COSTS On August 9, 2016, the Company entered into a separation agreement with an employee to pay $118,635 of accrued compensation over nine-years. This amount is included in accrued payroll and payroll related expenses in the accompanying consolidated balance sheets. This amount does not yield interest and matures as follows for the years ended December 31: 2021 $ 12,000 2022 12,000 2023 18,000 2024 18,000 2025 23,635 83,635 Less current portion (12,000 ) $ 71,635

Related Party Notes Payable

Related Party Notes Payable	12 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
Related Party Notes Payable	NOTE 6 – RELATED PARTY NOTES PAYABLE Related party notes payable consisted of the following as of December 31: 2020 2019 Inventory financing. $ 1,000,000 $ 1,000,000 Officer loan. 75,000 75,000 Promissory note 500,000 500,000 2020 2019 Promissory note. - - Promissory note. 94,000 - Promissory note. 100,000 - Total related party notes payable 1,769,000 1,575,000 Less current portion (769,000 ) (575,000 ) Long term related party notes payable $ 1,000,000 $ 1,000,000 Interest expense The Company incurred interest charges of $190,268 and $147,605 during the years ended December 31, 2020 and 2019, respectively, on these related party notes payable of which $116,826 and $47,413 was accrued and payable as of December 31, 2020 and 2019. Maturities Future maturities of these related party notes payable are as follows as of December 31: 2021 $ 769,000 2022 1,000,000 $ 1,769,000

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Notes Payable	NOTE 7 – NOTES PAYABLE On April 22, 2020, the Company received a Paycheck Protection Program (“PPP”) loan from a U.S. Small Business Administration (the “SBA”) lender for $211,300. Management believes the loan will be eligible for forgiveness in accordance with the terms of the program. On July 14, 2020, the Company issued a note payable in the amount of $25,000. This note accrued interest at 12% per annum, payable at maturity, and matured on July 31, 2020. On July 31, 2020, this note was repaid in full. Interest expense The Company incurred interest charges on these notes payable of $1,606 during the year ended December 31, 2020. The aggregate amount of accrued and unpaid interest on this note payable was $1,466 as of December 31, 2020. Other The Company also applied for the Economic Injury Disaster Loan (“EIDL”) from the SBA, which remains pending as of the date hereof. The Company received an EIDL advance amount of $10,000 during the year-ended December 31, 2020. According to the terms set forth by the SBA, regardless of whether the loan application is approved or declined, the advance does not need to be repaid; accordingly, the Company recognized the advance as other income.

Related Party Convertible Notes

Related Party Convertible Notes Payable	12 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
Related Party Convertible Notes Payable	NOTE 8 – RELATED PARTY CONVERTIBLE NOTES PAYABLE Related party convertible notes payable consisted of the following as of December 31: 2020 2019 Convertible note 2019-02. $ 815,217 $ 815,217 2020 2019 Convertible note 2019-07. 217,391 217,391 Officer convertible note. 100,000 100,000 2020 2019 Convertible note 2020-11. 271,739 - Convertible note 2020-16. - - Total related party convertible notes payable 1,404,347 1,132,608 Less original issue discounts (104,347 ) (82,608 ) Related party convertible notes payable, net 1,300,000 1,050,000 Less discounts for conversion rights, beneficial conversion features, and detachable warrants (386,310 ) (693,316 ) Plus amortization of discounts 420,606 295,037 Total related party convertible notes payable, net $ 1,334,296 $ 651,721 Discounts Total discounts (original issue discounts plus discounts for conversion rights, beneficial conversion features, and detachable warrants) of $490,658 are amortized using the interest method, which resulted in amortization recorded as interest expense of $478,072 for the year ended December 31, 2020, with total accumulated amortization equal to $420,606 as of December 31, 2020. Modifications The Company evaluated changes to the terms of certain related party convertible notes payable in accordance with FASB ASC No. 470-50, Debt Modifications and Extinguishments In February 2020, the Company adjusted the conversion price of certain related party convertible notes payable in accordance with their terms, which triggered modification accounting and resulted in a gain of $258,903. On June 30, 2020, the Company extended the maturity dates of the related party convertible notes payable as described in the table above. Management compared the present values of these notes before and after the extensions, noting that the change in present value was less than 10%. As such, these notes were determined to not be substantially different and no changes in values were recognized. Interest expense The Company incurred interest charges on these related party convertible notes payable of $102,905 and $35,132 during the years ended December 31, 2020 and 2019, respectively, on these related party convertible notes payable of which $10,024 and $8,205 was accrued and payable as of December 31, 2020 and 2019. Maturities Future maturities of these related party convertible notes payable are as follows as of December 31: 2021 $ 1,404,347 $ 1,404,347

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Convertible Notes Payable	NOTE 9 – CONVERTIBLE NOTES PAYABLE Convertible notes payable consisted of the following as of December 31: 2020 2019 Convertible note 2019-01. $ - $ 150,000 Convertible note 2019-03. 108,696 108,696 2020 2019 Convertible note 54,348 54,348 Convertible note 27,174 27,174 2020 2019 Convertible note 27,174 27,174 Convertible note 108,696 108,696 2020 2019 Convertible note 27,174 27,174 Convertible note 16,304 16,304 2020 2019 Convertible note 10,870 - Convertible note 133,272 - 2020 2019 Convertible note 52,632 - Convertible note - - 2020 2019 Convertible note 260,000 - 2020 2019 Convertible note 500,000 - 2020 2019 Convertible note 100,000 - Convertible note 25,000 - 2020 2019 Convertible note 100,000 - Convertible note 15,000 - 2020 2019 Convertible note 25,000 - Convertible note 108,696 - 2020 2019 Convertible note 60,000 - Convertible note 20,000 - 2020 2019 Convertible note 55,556 - Total convertible notes payable 1,835,592 519,566 Less original issue discounts (107,320 ) (29,566 ) Convertible notes payable, net 1,728,272 490,000 Less discounts for conversion rights, beneficial conversion features, debt issuance costs, extension fees, and detachable warrants (1,062,054 ) (253,675 ) Plus amortization of discounts 802,313 121,964 Total convertible notes payable, net $ 1,468,531 $ 358,289 Discounts Total discounts (original issue discounts plus discounts for conversion rights, beneficial conversion features, debt issuance costs, extension fees and detachable warrants) of $1,169,372 are amortized using the interest method, which resulted in amortization recorded as interest expense of $1,363,316 and $121,964 for the years ended December 31, 2020 and 2019, respectively, with total accumulated amortization equal to $802,313 as of December 31, 2020. Modifications The Company evaluated changes to the terms of certain convertible notes payable in accordance with FASB ASC No. 470-50, Debt Modifications and Extinguishments In February 2020, the Company adjusted the conversion price of a convertible note payable in accordance with its terms, which triggered modification accounting and resulted in a gain of $95,888. On June 30, 2020, the Company extended the maturity dates of certain convertible notes payable as described in the table above. Management compared the present values of these notes before and after the extensions, noting that the change in present value was less than 10%. As such, these notes were determined to not be substantially different and no changes in values were recognized. In September 2020, the Company adjusted the conversion price of a convertible note payable in accordance with its terms, which triggered modification accounting and resulted in a gain of $40,133. In November 2020, the Company extended the maturity date of a certain convertible note payable as described in the table above. Management compared the present value of this note before and after the extension, noting that the change in present value was greater than 10%, which triggered an accounting extinguishment in such period. In November 2020, the Company extended the maturity date and the fixed conversion price and prepayment period of certain convertible notes payable as described in the table above. Management compared the present values of these notes before and after the extensions, noting that the change in present value was less than 10%. As such, these notes were determined to not be substantially different and no changes in values were recognized. Interest expense The Company incurred interest charges on these convertible notes payable of $142,227 and $17,877 during the years ended December 31, 2020 and 2019, respectively, of which $67,648 and $13,114 was accrued and payable as of December 31, 2020 and 2019. Maturities Future maturities of these convertible notes payable are as follows as of December 31: 2021 $ 1,835,592 $ 1,835,592

Derivative Financial Instrument

Derivative Financial Instruments	12 Months Ended
	Dec. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	NOTE 10 – DERIVATIVE FINANCIAL INSTRUMENTS The Company has identified the embedded derivatives related to the convertible notes described in Notes 8 and 9. These embedded derivatives included certain conversion and reset features. The accounting treatment of derivative financial instruments requires that the Company record fair value of these derivative liabilities as of the issuance date of the convertible notes and each subsequent reporting date as well as upon modification, repayment, or extinguishment of the convertible notes. Derivative liabilities are eliminated upon repayment or extinguishment of the convertible notes and recorded as an adjustment to additional paid in capital. The Company estimates the fair value of these derivative liabilities using the Black-Scholes valuation model. The initial value is used in the determination of a note discount with each subsequent change in fair value as a component of operations. The range of fair value assumptions used for derivative financial instruments during the year ended December 31, 2020, were as follows: Dividend yield 0.0 % Risk-free rate 0.10% - 1.43 % Volatility 147% - 190 % Expected term 1 year The expected dividend yield is zero, because the Company does not anticipate paying a dividend within the relevant timeframe. The risk-free interest rate used is based on the U.S. Treasury constant maturity rate in effect at the time of valuation for the expected term of the derivative liabilities to be valued. The expected volatility is calculated based on the historical volatility of the Company. The Company recognized derivative liabilities for the years ended December 31, 2020 and 2019, as follows: Derivative liabilities as of January 1, 2019 $ - Valuation upon issuance 323,675 Revaluation upon modification 147,325 Change in fair value 356,314 Derivative liabilities as of December 31, 2019 827,314 Valuation upon issuance 433,672 Revaluation upon modification (344,137 ) Change in fair value (222,707 ) Elimination upon extinguishment (458,977 ) Derivative liabilities as of December 31, 2020 $ 235,165 The following table presents the three-level hierarchy prescribed by U.S. GAAP for derivative liabilities since it is a liability that is measured and recognized at fair value on a recurring basis as of: Level 1 Level 2 Level 3 Change in Fair Value December 31, 2019 $ - $ - $ 827,314 $ 356,314 December 31, 2020 $ - $ - $ 235,165 $ (222,707 )

Stockholders' Deficit

Stockholders' Deficit	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Stockholders' Deficit	NOTE 11 – STOCKHOLDERS’ DEFICIT Preferred stock issuance On January 11, 2021, the Company sold 2,000 shares of Series A Preferred Stock for an aggregate purchase price of $50,000. In accordance with the Certificate of Designation of Series A Preferred Stock dated January 7, 2021: (i) each share of Series A Preferred Stock shall be convertible, at the option of the holder thereof, from and after October 15, 2022, into shares of common stock; (ii) all outstanding shares of Series A Preferred Stock shall be automatically converted into shares of common stock in the event any of the Company’s securities are listed for trading on any national exchange; and (iii) the Company may redeem any or all of the outstanding shares of Series A Preferred Stock at any time after October 15, 2023. Reverse stock split On January 15, 2020, the Company effected a 200-for-1 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding shares of common stock. The Reverse Stock Split did not change the number of shares of common stock authorized for issuance, the par value of the common stock, or any other terms of the common stock. No fractional shares were issued in the Reverse Stock Split and any remaining share fractions were rounded up to the next whole share. Under the terms and conditions of outstanding options, warrants, and other convertible securities, the number of underlying shares of common stock and the exercise prices or conversion prices thereof were proportionately adjusted for the Reverse Stock Split. All share and per share amounts reported in the consolidated financial statements reflect the Reverse Stock Split. Self-directed stock issuance 2019 During the year ended December 31, 2019, the Company sold securities in a self-directed offering to existing stockholders of the Company in the aggregate amount of $245,000, respectively, at $60 per unit. Each $60 unit consisted of 2 shares of restricted common stock (8,169 shares) and a five-year warrant to purchase 1 share of restricted common stock (4,085 warrant shares) at $40 per share. Conversion of convertible note On December 17, 2020, the Company issued 18,000 shares of restricted common stock upon the full conversion of a convertible note in the principal amount of $90,000. Shares outstanding As of December 31, 2020 and 2019, the Company had a total of 794,183 and 687,564 shares of common stock outstanding, respectively.

Stock Grants

Stock Grants	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Stock Grants	NOTE 12 – STOCK GRANTS Stock grants to convertible note holders During the year ended December 31, 2020, the Company granted convertible note holders an aggregate of 81,409 shares of restricted common stock as consideration for commitment fees (“commitment shares”). 27,777 commitment shares were cancelled upon repayment of a convertible note in accordance with its terms and another 27,777 commitment shares are returnable upon repayment of a convertible note in accordance with its terms. During the year ended December 31, 2020, the Company granted a convertible note holder 6,250 shares of restricted common stock as consideration for extension fees. Director stock grants During the years ended December 31, 2020 and 2019, the Company granted its independent directors an aggregate of 28,737 and 11,054, respectively, shares of restricted common stock. These shares were fully vested upon issuance. The expense recognized for these grants based on the fair value on the grant date was $75,000 and $350,000 for the years ended December 31, 2020 and 2019, respectively. Effective as of the quarter ended March 31, 2020, certain independent directors elected to receive compensation in the form of warrants rather than stock. Consultant stock grants During the year ended December 31, 2020, the Company did not grant consultants any stock and accordingly did not recognize any related expense. During the year ended December 31, 2019, the Company granted consultants an aggregate of 750 shares of restricted common stock, which were fully vested upon issuance. The expense recognized for these grants based on the fair value on the grant date was $16,650.

Stock Option Plans

Stock Option Plans	12 Months Ended
	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Stock Option Plans	NOTE 13 – STOCK OPTION PLANS On February 7, 2014, the Company adopted the 2014 Equity Compensation Plan. Under this plan, the Company may issue options to purchase shares of common stock to employees, directors, advisors, and consultants. The aggregate number of shares reserved under this plan upon adoption was 152,101. On April 16, 2015, the majority stockholder of the Company approved an increase in the shares reserved under this plan by 75,000 shares. On December 4, 2018, the stockholders of the Company approved an increase in the shares reserved under this plan by an additional 25,000 shares and authorized the annual increase of the shares reserved under this plan on January 1st of each year, at the discretion of the Board of Directors, by up to such number of shares that is equal to four percent (4%) of the shares of common stock issued and outstanding as of December 31st of the previous calendar year. Accordingly, effective as of January 1, 2020, the shares reserved under this plan were increased by 27,000 shares, and effective as of January 1, 2021, the shares reserved under this plan were increased by 31,000 shares. An aggregate of 279,101 shares of common stock were reserved for issuance under this plan as of December 31, 2020, and an aggregate of 310,101 shares of common stock are presently reserved for issuance under this plan. Under the terms of the 2014 Equity Compensation Plan and the 2006 Stock Incentive Plan (collectively, the “Plans”), incentive stock options may be granted to employees at a price per share not less than 100% of the fair market value at date of grant. If the incentive stock option is granted to a 10% stockholder, then the purchase or exercise price per share shall not be less than 110% of the fair market value per share of common stock on the grant date. Non-statutory stock options and restricted stock may be granted to employees, directors, advisors, and consultants at a price per share, not less than 100% of the fair market value at date of grant. Options granted are exercisable, unless specified differently in the grant documents, over a default term of ten years from the date of grant and generally vest over a period of four years. A summary of stock option activity is as follows: Options Weighted Weighted Aggregate Outstanding January 1, 2019 202,537 $ 80.13 4.52 $ 987,064 Exercisable January 1, 2019 185,837 $ 82.13 4.10 $ 967,064 Canceled (291 ) Granted - Exercised - Expired - Outstanding December 31, 2019 202,246 $ 80.14 3.52 $ - Exercisable December 31, 2019 192,108 $ 81.32 3.26 $ - Canceled - Granted - Exercised - Expired (35,741 ) Outstanding December 31, 2020 166,505 $ 85.81 3.14 $ - Exercisable December 31, 2020 160,536 $ 87.00 2.98 $ - The aggregate intrinsic value in the table above is before applicable income taxes and represents the excess amount over the exercise price option recipients would have received if all options had been exercised on December 31, 2020, based on a valuation of the Company’s stock for that day. A summary of the Company’s non-vested options for the years ended December 31, 2020 and 2019, is presented below: Non-vested at January 1, 2019 16,700 Granted - Vested (6,271 ) Canceled (291 ) Non-vested at December 31, 2019 10,138 Granted - Vested (4,169 ) Canceled - Non-vested at December 31, 2020 5,969 Option valuation The Company estimates the fair value of stock options granted on each grant date using the Black-Scholes valuation model and recognizes an expense ratably over the requisite service period. The expected dividend yield is zero, because the Company does not anticipate paying a dividend within the relevant timeframe. The risk-free interest rate used is based on the U.S. Treasury constant maturity rate in effect at the time of grant for the expected term of the stock options to be valued. The expected volatility is calculated based on the historical volatility of the Company. Due to a lack of historical information needed to estimate the Company’s expected term, it is estimated using the simplified method allowed. The Company records forfeitures as they occur and reverses compensation cost previously recognized, in the period the award is forfeited, for an award that is forfeited before completion of the requisite service period. During the years ended December 31, 2020 and 2019, no options were granted. Stock-based compensation expense The Company recognized stock-based compensation expense related to options during the years ended December 31: 2020 2019 Service provider compensation $ 98,750 $ 177,500 Employee compensation 158,750 164,438 Total $ 257,500 $ 341,938 Option expiration During the year ended December 31, 2020, options to purchase an aggregate of 35,741 shares of common stock expired. During the year ended December 31, 2019, no options expired.

Warrants

Warrants	12 Months Ended
	Dec. 31, 2020
Warrants and Rights Note Disclosure [Abstract]
Warrants	NOTE 14 – WARRANTS The following is a summary of the Company’s warrant activity: Warrants Weighted Weighted Aggregate Outstanding January 1, 2019 590,340 $ 40.65 2.32 $ 7,846,743 Exercisable January 1, 2019 590,340 $ 40.65 2.32 $ 7,846,743 Canceled - Granted 20,985 Exercised - Expired (94,577 ) Outstanding December 31, 2019 516,748 $ 24.60 1.86 $ - Exercisable December 31, 2019 516,748 $ 24.60 1.86 $ - Canceled - Granted 349,358 Exercised - Expired (85,171 ) Outstanding December 31, 2020 780,935 $ 15.47 3.53 $ - Exercisable December 31, 2020 780,935 $ 15.47 3.53 $ - Warrant valuation The Company estimates the fair value of warrants granted on each grant date using the Black-Scholes valuation model. The range of fair value assumptions related to warrants issued were as follows for the years ended December 31: 2020 2019 Dividend yield 0.0 % 0.0 % Risk-free rate 0.13% – 1.55 % 1.34% – 2.37 % Volatility 143% – 207 % 145% – 168 % Expected term 2 – 5 years 2 – 2.5 years The expected dividend yield is zero, because the Company does not anticipate paying a dividend within the relevant timeframe. The risk-free interest rate used is based on the U.S. Treasury constant maturity rate in effect at the time of grant for the expected term of the warrants to be valued. The expected volatility is calculated based on the historical volatility of the Company. Due to a lack of historical information needed to estimate the Company’s expected term, it is estimated using the simplified method allowed. Convertible note warrants During the year ended December 31, 2020, warrants to purchase 230,670 shares of common stock at $4.50 to $10.00 per share were issued in connection with the issuance of convertible notes. During the year ended December 31, 2019, warrants to purchase 16,900 shares of common stock at $14 ($4.27 as adjusted upon dilutive issuance) to $40 per share were issued in connection with the issuance of convertible notes. These warrants were immediately vested and expire in five years. The value of the warrants was recorded as a discount on the convertible notes in the aggregate amount of $421,399 and $125,545 during the years ended December 31, 2020 and 2019, respectively. Director warrant grants During the year ended December 31, 2020, the Company granted its independent directors warrants as follows: Date of Grant Warrants Exercise Price March 31, 2020 12,756 $ 6.00 June 30, 2020 34,248 $ 2.25 September 30, 2020 25,952 $ 3.00 December 31, 2020 45,732 $ 1.70 These warrants were immediately vested and expire in ten years. During the year ended December 31, 2020, the Company recognized stock-based compensation expense related to these warrants in the aggregate amount of $300,000. During the year ended December 31, 2019, the Company did not recognize any stock-based compensation expense related to warrants. Warrant expiration During the year ended December 31, 2020, warrants to purchase an aggregate of 85,171 shares of common stock expired. During the year ended December 31, 2019, warrants to purchase an aggregate of 94,577 shares of common stock expired.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 15 – INCOME TAXES The following table presents a reconciliation of the statutory Federal rate and the Company’s effective tax rate for the years ended December 31: 2020 2019 Change in valuation allowance 19.02 % 12.80 % Debt instruments (2.57 )% 3.19 % Stock based compensation 2.63 % 2.92 % Accrued compensation 2.80 % 1.03 % Interest expense (2.26 )% 0.85 % Depreciation and amortization 1.37 % 0.16 % Other 0.00 % 0.04 % Tax benefit at Federal statutory rate (21.00 )% (21.00 )% Effective tax rate 0.00 % 0.00 % The effective tax rate for the three and years ended December 31, 2020 and 2019, differs from the statutory rate of 21% for the years ended December 31, 2020 and 2019, respectively, as a result of state taxes (net of Federal benefit), permanent differences, and a reserve against deferred tax assets. There was not a provision for income taxes for the years ended December 31, 2020 and 2019. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The following table presents significant components of the Company’s deferred tax assets and liabilities for the years ended December 31: 2020 2019 DEFERRED TAX ASSETS, net: Net operating loss carryforwards $ 12,186,945 $ 10,670,455 Accrued compensation 1,341,779 1,211,630 Stock based compensation 175,676 196,809 Credit carryforwards 58,122 58,122 Interest expenses 57,333 57,332 Depreciation and amortization (155,304 ) (208,482 ) Debt instruments (14,944 ) (408,144 ) Total 13,649,607 11,577,722 Less valuation allowance (13,649,607 ) (11,577,722 ) NET DEFERRED TAX ASSETS $ - $ - As of December 31, 2020, the Company had a Federal net operating loss carryforward of $46,286,607. In addition, the Company had a net operating loss carryforward for Hawaii income tax purposes of $36,410,868 as of December 31, 2020. The Company’s valuation allowance was primarily related to the operating losses. The valuation allowance is determined in accordance with the provisions of ASC No. 740, Income Taxes

Basic and Diluted Net Loss Per

Basic and Diluted Net Loss Per Share	12 Months Ended
	Dec. 31, 2020
Earnings Per Share [Abstract]
Basic and Diluted Net Loss Per Share	NOTE 16 – BASIC AND DILUTED NET LOSS PER SHARE The following table sets forth the computation of the Company’s basic and diluted net loss per share for: 2020 Net Loss (Numerator) Shares (Denominator) Per share Basic loss per share $ (5,055,507 ) 744,555 $ (6.79 ) Effect of dilutive securities—Common stock options, warrants, and convertible notes - - - Diluted loss per share $ (5,055,507 ) 744,555 $ (6.79 ) 2019 Net Loss (Numerator) Shares (Denominator) Per share Basic loss per share $ (5,093,037 ) 680,152 $ (7.49 ) Effect of dilutive securities—Common stock options and warrants - - - Diluted loss per share $ (5,093,037 ) 680,152 $ (7.49 ) The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive for the years ended December 31: 2020 2019 Common stock underlying convertible notes 638,247 105,360 Common stock underlying options 166,505 202,246 Common stock underlying warrants 780,935 516,748 Total common stock equivalents 1,585,687 824,354

Leases

Leases	12 Months Ended
	Dec. 31, 2020
Leases [Abstract]
Leases	NOTE 17 – LEASES Office lease The Company entered into an automatically renewable month-to-month lease for office space on August 13, 2010. Under the terms of this lease, the Company must provide a written notice 45 days prior to vacating the premises. Total rent expense under this agreement as amended was $36,777 and $37,915 for the years ended December 31, 2020 and 2019, respectively. Fleet lease In January 2018, the Company entered into a vehicle lease arrangement with a rental company for three vehicles. The terms of the leases require monthly payments of $1,619 for three years. These leases convert to month-to-month leases in January 2021 unless terminated. The Company terminated one lease in August of 2019, which reduced the monthly payments to $1,002. Total lease expense under this agreement was $15,315 and $16,174 for the years ended December 31, 2020 and 2019, respectively. The Company terminated the remaining two leases in January of 2021. Right-to-use leased asset and liability As a result of the adoption of ASU No. 2016-02, Leases Future minimum lease payments Future minimum lease payments are as follows for the years ended December 31: 2021 $ 962 962

Commitments

Commitments	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments	NOTE 18 – COMMITMENTS Patent license payable As part of the formation of the Company, a patent license was transferred to the Company. The original license began in 2006. Under the terms of the license the Company agreed to pay $10,000 per year through 2015 and royalties of 2% on any revenues resulting from the license. The license expired in February 2016. There were no revenues generated by this license. The remaining obligation of $20,000 as of December 31, 2020 and 2019, is recorded as a part of accounts payable on the consolidated balance sheets. Employee settlement As of December 31, 2020 and 2019, the Company owed a former employee a severance settlement payable in the amount of $50,000 for accrued vacation benefits. As part of the severance settlement, a stock option previously granted to the former employee was fully vested and extended.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	NOTE 19 – SUBSEQUENT EVENTS The Company evaluated all material events through the date the financials were ready for issuance and identified the following for additional disclosure. Preferred stock issuance On January 11, 2021, the Company sold 2,000 shares of Series A Preferred Stock for an aggregate purchase price of $50,000. In accordance with the Certificate of Designation of Series A Preferred Stock dated January 7, 2021: (i) each share of Series A Preferred Stock shall be convertible, at the option of the holder thereof, from and after October 15, 2022, into shares of common stock; (ii) all outstanding shares of Series A Preferred Stock shall be automatically converted into shares of common stock in the event any of the Company’s securities are listed for trading on any national exchange; and (iii) the Company may redeem any or all of the outstanding shares of Series A Preferred Stock at any time after October 15, 2023. Related party notes payable On January 1, 2021, an amendment to the revolving inventory financing facility issued January 11, 2019, in the aggregate amount of $1,000,000, provided that interest shall be payable at maturity. All other terms remain unchanged. On January 1, 2021, an amendment to the related party note payable issued December 30, 2020, in the original principal amount of $100,000, provided that interest shall be payable at maturity. All other terms remain unchanged. This note was subsequently amended as described below. On March 30, 2021, an amendment to the related party note payable issued December 30, 2020, in the original principal amount of $100,000, extended the maturity date to June 30, 2021. All other terms remain unchanged. Notes payable On February 6, 2021, the Company received a Second Draw Paycheck Protection Program (“PPP”) loan for $211,359. Under the terms of the program, the loan amount may be forgiven if certain terms and conditions are met. Related party convertible notes payable On January 1, 2021, amendments to the related party convertible notes payable issued July 19, 2019 (original principal amount of $815,217), October 16, 2019 (original principal amount of $217,391), November 15, 2019 (original principal amount of $100,000), and September 17, 2020 (original principal amount of $271,739), provided that interest shall be payable at maturity. All other terms remain unchanged. The amendments were not considered material modifications under ASC 470-50-40, and as a result, were not considered accounting extinguishments in the period the notes were modified. On January 28, 2021, the Company and the Chairman of the Board of Directors, as a lender to the Company, entered into a convertible note payable in the amount of $100,000. This note accrues interest at the rate of 8% per annum and matures on December 31, 2021. This note and accrued interest may convert into shares of common stock at $5.00 per share any time at the holder’s option. The Company has the right to prepay this note without penalty or premium. If this note has not been repaid or converted in full on or prior to the maturity date, then repayment of the outstanding principal balance shall be amortized over the following thirty-six (36) months. This note was also issued with a detachable warrant exercisable for 5 years to purchase 20,000 shares of common stock at $5.00 per share. On March 8, 2021, the Company and a current stockholder that beneficially owns more than 5% of the Company’s common stock, as a lender to the Company, entered into a convertible note payable in the amount of $150,000. This note accrues interest at the rate of 8% per annum and matures on March 8, 2022. This note and accrued interest may convert into shares of common stock at $5.00 per share any time at the holder’s option. The Company has the right to prepay this note without penalty or premium. If this note has not been repaid or converted in full on or prior to the maturity date, then repayment of the outstanding principal balance shall be amortized over the following thirty-six (36) months. This note was also issued with a detachable warrant exercisable for 5 years to purchase 30,000 shares of common stock at $5.00 per share. Convertible notes payable amendments On January 1, 2021, amendments to the convertible notes payable issued September 4, 2019 (original principal amount of $108,696), September 25, 2019 (original principal amount of $54,348), October 3, 2019 (original principal amount of $27,174), October 10, 2019 (original principal amount of $27,174), October 23, 2019 (original principal amount of $108,696), October 29, 2019 (original principal amount of $27,174), November 8, 2019 (original principal amount of $16,304), January 6, 2020 (original principal amount of $10,870), February 25, 2020 (original principal amount of $52,632), July 30, 2020 (original principal amount of $25,000), September 22, 2020 (original principal amount of $25,000), September 28, 2020 (original principal amount of $108,696), October 8, 2020 (original principal amount of $60,000), October 8, 2020 (original principal amount of $20,000), and December 28, 2020 (original principal amount of $55,556), provided that interest shall be payable at maturity. All other terms remain unchanged. The amendments were not considered material modifications under ASC 470-50-40, and as a result, were not considered accounting extinguishments in the period the notes were modified. On January 13, 2021, an amendment to the convertible note payable issued March 16, 2020, in the original principal amount of $250,000, extended the maturity date to February 28, 2021. The amendment also provided that the 27,777 shares of common stock issued in connection with the purchase of the note shall be subject to return if the note is fully repaid by February 28, 2021. As consideration for the extension, the Company paid an extension fee of $15,000 ($7,500 on January 28, 2021, and $7,500 on February 22, 2021). All other terms remain unchanged. The amendment to this note was not considered a material modification under ASC 470-50-40, and as a result, is not considered an accounting extinguishment in the period the note was modified. This note was subsequently amended as described below. On March 29, 2021, an amendment to the convertible note payable issued March 16, 2020, in the original principal amount of $250,000, extended the maturity date to May 25, 2021. The amendment also provided that the 27,777 shares of common stock issued in connection with the purchase of the note shall be subject to return if the note is fully repaid by May 25, 2021. As consideration for the extension, the Company agreed to pay an extension fee of $15,000 ($7,500 by April 22, 2021, and $7,500 by May 14, 2021). All other terms remain unchanged. The amendment to this note was not considered a material modification under ASC 470-50-40, and as a result, is not considered an accounting extinguishment in the period the note was modified. On January 19, 2021, an amendment to the convertible note payable issued May 14, 2020, in the original principal amount of $500,000, provided the Company with options to extend the period before the conversion price adjusts from a fixed price to a variable price at a discount to market and the period the Company may prepay the note without penalty or premium. The Company elected to extend such periods to nine (9) months following issuance (February 14, 2021) with payment of an extension fee of $25,000 ($12,500 on January 28, 2021, and $12,500 on February 12, 2021), to nine and one-half (9.5) months following issuance (February 28, 2021) with payment of an additional extension fee of $12,500 on February 26, 2021, to ten (10) months following issuance (March 14, 2021) with payment of an additional extension fee of $12,500 on March 12, 2021, and to ten and one-half (10.5) months following issuance (March 31, 2021) with payment of an additional extension fee of $12,500 on March 30, 2021. All other terms remain unchanged. Each amendment to extend the respective periods to this note was not considered a material modification under ASC 470-50-40, and as a result, is not considered an accounting extinguishment in the period the note was modified. On January 29, 2021, and March 31, 2021, amendments to the convertible note payable issued January 21, 2020, in the original principal amount of $262,500, provided terms for settlement of the note. In accordance with the amendment, the Company paid $130,000 to the holder ($100,000 on February 1, 2021, $10,000 on March 8, 2021, and $20,000 on March 31, 2021) in full settlement of the note. Convertible notes payable issuances On January 27, 2021, the Company issued a convertible note payable in the amount of $55,556 with an original issue discount of $5,556 in exchange for $50,000. This note accrues interest at 8% per annum and matures on December 31, 2021. This note and accrued interest may convert into shares of common stock at $5.00 per share any time at the holder’s option. The Company has the right to prepay this note without penalty or premium. If this note has not been repaid or converted in full on or prior to the maturity date, then repayment of the outstanding principal balance shall be amortized over the following thirty-six (36) months. This note was also issued with a detachable warrant exercisable for 5 years to purchase 15,000 shares of common stock at $5.00 per share. On March 26, 2021, the Company issued a convertible note payable in the amount of $100,000. This note accrues interest at 8% per annum and matures on March 31, 2022. This note and accrued interest may convert into shares of common stock at $5.00 per share any time at the holder’s option. The Company has the right to prepay this note without penalty or premium. If this note has not been repaid or converted in full on or prior to the maturity date, then repayment of the outstanding principal balance shall be amortized over the following thirty-six (36) months. This note was also issued with a detachable warrant exercisable for 5 years to purchase 20,000 shares of common stock at $5.00 per share.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of presentation The consolidated financial statements have been consistently prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and include the accounts of Cardax, Inc., and its wholly owned subsidiary, Cardax Pharma, Inc., and its predecessor, Cardax Pharmaceuticals, Inc., which was merged with and into Cardax, Inc. All significant intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and the accompanying notes. Estimates in these consolidated financial statements include asset valuations, estimates of future cash flows from and the economic useful lives of long-lived assets, valuations of derivative liabilities, warrants, beneficial conversion features, and stock compensation, certain accrued liabilities, income taxes and tax valuation allowances, and fair value estimates. Despite management’s intention to establish accurate estimates and reasonable assumptions, actual results could differ materially from these estimates and assumptions.
Cash	Cash The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents. The Company held no cash equivalents as of December 31, 2020 and 2019. The Company maintains cash deposit accounts at one financial institution. Accounts at this institution are insured by the Federal Deposit Insurance Corporation up to $250,000. The Company’s cash balance at times may exceed these limits. As of December 31, 2020 and 2019, the Company had $0 in excess of federally insured limits on deposit.
Accounts Receivable	Accounts receivable Accounts receivable, net, of $0 and $205,768 as of December 31, 2020 and 2019, respectively, consists of amounts due from sales of dietary supplements. It is the Company’s policy to provide for an allowance for doubtful collections based upon a review of outstanding receivables, historical collection information, and existing economic conditions. Normal receivables are due 60 days after the issuance of the invoice. Receivables past due more than 90 days are considered delinquent. Delinquent receivables are written off based on individual credit evaluation and specific circumstances of the customer. No allowance was deemed necessary as of December 31, 2020 and 2019, respectively.
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value. Cost is determined using the average cost method. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. Inventory costs include third party costs for finished goods. The Company utilizes contract manufacturers and receives inventory in finished form. When necessary, the Company provides a reserve against inventory for known or expected inventory obsolescence. The reserve is determined by specific review of inventory items for product age and quality that may affect salability. There were no reserves necessary for inventory as of December 31, 2020 and 2019.
Notes Payable	Notes payable The Company issued various notes payable to related and non-related parties. These notes payable included original issue discounts, detachable warrants, conversion features, beneficial conversion features, debt issuance costs, and modifications. ● Original issue discounts. Interest and Imputation of Interest ● Detachable warrants. Debt ● Conversion features Derivatives and Hedging; Embedded Derivatives ● Beneficial conversion features. Debt ● Debt issuance costs. Debt ● Debt modifications. Debt Modifications and Extinguishments
Stock Issuance Costs	Stock issuance costs Stock issuance costs related to financing are accounted for as a reduction in stock proceeds in accordance with ASC No. 340-10, Other Assets and Deferred Costs
Revenue from Contracts with Customers	Revenue from contracts with customers In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606) Under ASC No. 606, in order to recognize revenue, the Company is required to identify an approved contract with commitments to preform respective obligations, identify rights of each party in the transaction regarding goods to be transferred, identify the payment terms for the goods transferred, verify that the contract has commercial substance, and verify that collection of substantially all consideration is probable. The Company recognizes revenues from its contracts with customers for its products through wholesale and e-commerce channels when goods and services have been identified, the payment terms agreed to, the contract has commercial substance, both parties have approved the contract, and it is probable that the Company will collect all substantial consideration. The following table presents our revenues disaggregated by revenue source and geographical location. Sales and usage-based taxes are included as a component of revenues for the years ended December 31: Geographical area Source 2020 2019 United States Nutraceuticals $ 528,574 $ 705,694 Hong Kong Nutraceuticals $ 10,372 $ 5,255 Sales discounts, rebates, promotional amounts to vendors, and returns and allowances are recorded as a reduction to sales in the period in which sales are recorded. The Company records shipping charges and sales tax gross in revenues and cost of goods sold. Sales discounts and other adjustments are recorded at the time of sale.
Cost of Goods Sold	Cost of goods sold Cost of goods sold is comprised of costs to manufacture or acquire products sold to customers, direct and indirect distribution costs, and other costs incurred in the sale of goods.
Shipping and Handling Costs	Shipping and handling costs Shipping and handling costs are included in cost of goods sold. Shipping and handling costs were $11,310 and $19,999 for the years ended December 31, 2020 and 2019, respectively.
Sales and Use Tax	Sales and use tax Revenues, as presented on the accompanying income statement, include taxes collected from customers and remitted to governmental authorities. Such taxes were $3,045 and $3,018 for the years ended December 31, 2020 and 2019, respectively.
Research and Development	Research and development Research and development costs are expensed as incurred and consists primarily of manufacturing of products, third-party research, clinical studies, laboratory supplies, and scientific advisory boards. The focus of these costs is on the development of astaxanthin, zeaxanthin, and related compounds. For the years ended December 31, 2020 and 2019, research and development costs were $136,780 and $315,994, respectively.
Advertising	Advertising Advertising costs are expensed as incurred and are included as an element of sales and marketing costs in the accompanying consolidated statements of operations. For the years ended December 31, 2020 and 2019, advertising costs were $27,366 and $161,468, respectively.
Income Taxes	Income taxes The Company accounts for income taxes under an asset and liability approach. Deferred income taxes reflect the impact of temporary differences between assets and liabilities recognized for financial reporting purposes and the amounts recognized for income tax reporting purposes, net operating loss carryforwards, and other tax credits measured by applying currently enacted tax laws. When necessary, a valuation allowance is provided to reduce deferred tax assets to an amount that is more likely than not to be realized. The Company determines whether a tax position is more likely than not to be sustained upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The Company uses a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon tax authority examination, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. The Company files income tax returns in the United States (“U.S.”), Hawaii, California, New York, and New York City jurisdictions. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment to apply. The federal, state, and city income tax returns of the Company are subject to examination by the IRS, state, and city taxing authorities, generally for three years after they were filed. The Company did not recognize any tax liabilities for income taxes associated with unrecognized tax benefits as of December 31, 2020 and 2019. The Company’s policy is to include interest and penalties related to unrecognized tax benefits, if any, within the provision for income taxes in the consolidated statements of operations.
Fair Value Measurements	Fair value measurements U.S. GAAP establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are described below: Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access. Level 2: Inputs to the valuation methodology include: ● Quoted prices for similar assets or liabilities in active markets; ● Quoted prices for identical or similar assets or liabilities in inactive markets; ● Inputs other than quoted prices that are observable for the asset or liability; and ● Inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability. Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement. The asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.
Stock Based Compensation	Stock based compensation The Company accounts for stock-based compensation costs under the provisions of FASB’s Accounting Standards Codification ASC No. 718, Compensation—Stock Compensation Equity
Reclassifications	Reclassifications The Company has made certain reclassifications to conform its prior periods’ data to the current presentation. These reclassifications had no effect on the reported results of operations or cash flows.
Basic and Diluted Net Loss Per Share	Basic and diluted net loss per share Basic earnings per common share is calculated by dividing net loss for the year by the weighted average number of common shares outstanding during the year. Diluted earnings per common share is calculated by dividing net loss for the year by the sum of the weighted average number of common shares outstanding during the year plus the number of potentially dilutive common shares (“dilutive securities”) that were outstanding during the year. Dilutive securities include options granted pursuant to the Company’s stock option plans, and warrants issued to non-employees. Potentially dilutive securities are excluded from the computation of earnings per share in periods in which a net loss is reported, as their effect would be antidilutive.
Recently Adopted Accounting Pronouncements	Recently adopted accounting pronouncements In November 2019, the FASB issued ASU No. 2019-08, Compensation—Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606)
Recently Issued Accounting Pronouncements	Recently issued accounting pronouncements In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity In December 2019, the FASB Issued ASU No. 2019-12, Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Schedule of Revenues Disaggregated by Revenue Source and Geographical Location	The following table presents our revenues disaggregated by revenue source and geographical location. Sales and usage-based taxes are included as a component of revenues for the years ended December 31: Geographical area Source 2020 2019 United States Nutraceuticals $ 528,574 $ 705,694 Hong Kong Nutraceuticals $ 10,372 $ 5,255

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2020
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories consist of the following as of December 31: 2020 2019 Raw materials $ 759,400 $ 763,800 Finished goods 234,919 414,031 Total inventories $ 994,319 $ 1,177,831

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	12 Months Ended
	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets, Net	Intangible assets, net, consists of the following as of December 31: 2020 2019 Patents $ 499,106 $ 614,003 Less accumulated amortization (256,742 ) (332,081 ) 242,364 281,922 Patents pending 60,047 138,451 Total intangible assets, net $ 302,411 $ 420,373

Accrued Separation Costs (Table

Accrued Separation Costs (Tables)	12 Months Ended
	Dec. 31, 2020
Payables and Accruals [Abstract]
Schedule of Accrued Payroll and Payroll Related Expenses	This amount does not yield interest and matures as follows for the years ended December 31: 2021 $ 12,000 2022 12,000 2023 18,000 2024 18,000 2025 23,635 83,635 Less current portion (12,000 ) $ 71,635

Related Party Notes Payable (Ta

Related Party Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
Schedule of Related Party Notes Payable	Related party notes payable consisted of the following as of December 31: 2020 2019 Inventory financing. $ 1,000,000 $ 1,000,000 Officer loan. 75,000 75,000 Promissory note 500,000 500,000 2020 2019 Promissory note. - - Promissory note. 94,000 - Promissory note. 100,000 - Total related party notes payable 1,769,000 1,575,000 Less current portion (769,000 ) (575,000 ) Long term related party notes payable $ 1,000,000 $ 1,000,000
Schedule of Related Party Future Maturities of Notes Payable	Future maturities of these related party notes payable are as follows as of December 31: 2021 $ 769,000 2022 1,000,000 $ 1,769,000

Related Party Convertible Not_2

Related Party Convertible Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2020
Related Party Transactions [Abstract]
Schedule of Related Party Convertible Notes Payable	Related party convertible notes payable consisted of the following as of December 31: 2020 2019 Convertible note 2019-02. $ 815,217 $ 815,217 2020 2019 Convertible note 2019-07. 217,391 217,391 Officer convertible note. 100,000 100,000 2020 2019 Convertible note 2020-11. 271,739 - Convertible note 2020-16. - - Total related party convertible notes payable 1,404,347 1,132,608 Less original issue discounts (104,347 ) (82,608 ) Related party convertible notes payable, net 1,300,000 1,050,000 Less discounts for conversion rights, beneficial conversion features, and detachable warrants (386,310 ) (693,316 ) Plus amortization of discounts 420,606 295,037 Total related party convertible notes payable, net $ 1,334,296 $ 651,721
Schedule of Related Party Future Maturities of Convertible Notes Payable	Future maturities of these related party convertible notes payable are as follows as of December 31: 2021 $ 1,404,347 $ 1,404,347

Convertible Notes Payable (Tabl

Convertible Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable	Convertible notes payable consisted of the following as of December 31: 2020 2019 Convertible note 2019-01. $ - $ 150,000 Convertible note 2019-03. 108,696 108,696 2020 2019 Convertible note 54,348 54,348 Convertible note 27,174 27,174 2020 2019 Convertible note 27,174 27,174 Convertible note 108,696 108,696 2020 2019 Convertible note 27,174 27,174 Convertible note 16,304 16,304 2020 2019 Convertible note 10,870 - Convertible note 133,272 - 2020 2019 Convertible note 52,632 - Convertible note - - 2020 2019 Convertible note 260,000 - 2020 2019 Convertible note 500,000 - 2020 2019 Convertible note 100,000 - Convertible note 25,000 - 2020 2019 Convertible note 100,000 - Convertible note 15,000 - 2020 2019 Convertible note 25,000 - Convertible note 108,696 - 2020 2019 Convertible note 60,000 - Convertible note 20,000 - 2020 2019 Convertible note 55,556 - Total convertible notes payable 1,835,592 519,566 Less original issue discounts (107,320 ) (29,566 ) Convertible notes payable, net 1,728,272 490,000 Less discounts for conversion rights, beneficial conversion features, debt issuance costs, extension fees, and detachable warrants (1,062,054 ) (253,675 ) Plus amortization of discounts 802,313 121,964 Total convertible notes payable, net $ 1,468,531 $ 358,289
Schedule of Future Maturities of Convertible Notes Payable	Future maturities of these convertible notes payable are as follows as of December 31: 2021 $ 1,835,592 $ 1,835,592

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Fair Value Assumptions Related to Option Issued	The range of fair value assumptions used for derivative financial instruments during the year ended December 31, 2020, were as follows: Dividend yield 0.0 % Risk-free rate 0.10% - 1.43 % Volatility 147% - 190 % Expected term 1 year The following table presents the three-level hierarchy prescribed by U.S. GAAP for derivative liabilities since it is a liability that is measured and recognized at fair value on a recurring basis as of: Level 1 Level 2 Level 3 Change in Fair Value December 31, 2019 $ - $ - $ 827,314 $ 356,314 December 31, 2020 $ - $ - $ 235,165 $ (222,707 )
Schedule of Recognized Derivative Liabilities	The Company recognized derivative liabilities for the years ended December 31, 2020 and 2019, as follows: Derivative liabilities as of January 1, 2019 $ - Valuation upon issuance 323,675 Revaluation upon modification 147,325 Change in fair value 356,314 Derivative liabilities as of December 31, 2019 827,314 Valuation upon issuance 433,672 Revaluation upon modification (344,137 ) Change in fair value (222,707 ) Elimination upon extinguishment (458,977 ) Derivative liabilities as of December 31, 2020 $ 235,165

Stock Option Plans (Tables)

Stock Option Plans (Tables)	12 Months Ended
	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Schedule of Stock Option Activity	A summary of stock option activity is as follows: Options Weighted Weighted Aggregate Outstanding January 1, 2019 202,537 $ 80.13 4.52 $ 987,064 Exercisable January 1, 2019 185,837 $ 82.13 4.10 $ 967,064 Canceled (291 ) Granted - Exercised - Expired - Outstanding December 31, 2019 202,246 $ 80.14 3.52 $ - Exercisable December 31, 2019 192,108 $ 81.32 3.26 $ - Canceled - Granted - Exercised - Expired (35,741 ) Outstanding December 31, 2020 166,505 $ 85.81 3.14 $ - Exercisable December 31, 2020 160,536 $ 87.00 2.98 $ -
Schedule of Non-vested Shares Granted Under Stock Option Plan	A summary of the Company’s non-vested options for the years ended December 31, 2020 and 2019, is presented below: Non-vested at January 1, 2019 16,700 Granted - Vested (6,271 ) Canceled (291 ) Non-vested at December 31, 2019 10,138 Granted - Vested (4,169 ) Canceled - Non-vested at December 31, 2020 5,969
Schedule of Recognized Stock Based Compensation Expense	The Company recognized stock-based compensation expense related to options during the years ended December 31: 2020 2019 Service provider compensation $ 98,750 $ 177,500 Employee compensation 158,750 164,438 Total $ 257,500 $ 341,938

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Dec. 31, 2020
Warrants and Rights Note Disclosure [Abstract]
Schedule of Stock Warrants Activity	The following is a summary of the Company’s warrant activity: Warrants Weighted Weighted Aggregate Outstanding January 1, 2019 590,340 $ 40.65 2.32 $ 7,846,743 Exercisable January 1, 2019 590,340 $ 40.65 2.32 $ 7,846,743 Canceled - Granted 20,985 Exercised - Expired (94,577 ) Outstanding December 31, 2019 516,748 $ 24.60 1.86 $ - Exercisable December 31, 2019 516,748 $ 24.60 1.86 $ - Canceled - Granted 349,358 Exercised - Expired (85,171 ) Outstanding December 31, 2020 780,935 $ 15.47 3.53 $ - Exercisable December 31, 2020 780,935 $ 15.47 3.53 $ -
Schedule of Fair Value of Warrant Valuations	The Company estimates the fair value of warrants granted on each grant date using the Black-Scholes valuation model. The range of fair value assumptions related to warrants issued were as follows for the years ended December 31: 2020 2019 Dividend yield 0.0 % 0.0 % Risk-free rate 0.13% – 1.55 % 1.34% – 2.37 % Volatility 143% – 207 % 145% – 168 % Expected term 2 – 5 years 2 – 2.5 years
Schedule of Independent Directors Warrants	During the year ended December 31, 2020, the Company granted its independent directors warrants as follows: Date of Grant Warrants Exercise Price March 31, 2020 12,756 $ 6.00 June 30, 2020 34,248 $ 2.25 September 30, 2020 25,952 $ 3.00 December 31, 2020 45,732 $ 1.70

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Schedule of Effective Income Taxes Rate	The following table presents a reconciliation of the statutory Federal rate and the Company’s effective tax rate for the years ended December 31: 2020 2019 Change in valuation allowance 19.02 % 12.80 % Debt instruments (2.57 )% 3.19 % Stock based compensation 2.63 % 2.92 % Accrued compensation 2.80 % 1.03 % Interest expense (2.26 )% 0.85 % Depreciation and amortization 1.37 % 0.16 % Other 0.00 % 0.04 % Tax benefit at Federal statutory rate (21.00 )% (21.00 )% Effective tax rate 0.00 % 0.00 %
Schedule of Deferred Income Tax Assets and Liabilities	The following table presents significant components of the Company’s deferred tax assets and liabilities for the years ended December 31: 2020 2019 DEFERRED TAX ASSETS, net: Net operating loss carryforwards $ 12,186,945 $ 10,670,455 Accrued compensation 1,341,779 1,211,630 Stock based compensation 175,676 196,809 Credit carryforwards 58,122 58,122 Interest expenses 57,333 57,332 Depreciation and amortization (155,304 ) (208,482 ) Debt instruments (14,944 ) (408,144 ) Total 13,649,607 11,577,722 Less valuation allowance (13,649,607 ) (11,577,722 ) NET DEFERRED TAX ASSETS $ - $ -

Basic and Diluted Net Loss Pe_2

Basic and Diluted Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2020
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Loss Per Share	The following table sets forth the computation of the Company’s basic and diluted net loss per share for: 2020 Net Loss (Numerator) Shares (Denominator) Per share Basic loss per share $ (5,055,507 ) 744,555 $ (6.79 ) Effect of dilutive securities—Common stock options, warrants, and convertible notes - - - Diluted loss per share $ (5,055,507 ) 744,555 $ (6.79 ) 2019 Net Loss (Numerator) Shares (Denominator) Per share Basic loss per share $ (5,093,037 ) 680,152 $ (7.49 ) Effect of dilutive securities—Common stock options and warrants - - - Diluted loss per share $ (5,093,037 ) 680,152 $ (7.49 )
Schedule of Shares of Common Stock Equivalents Were Excluded from Computation of Diluted Net Loss Per Share	The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive for the years ended December 31: 2020 2019 Common stock underlying convertible notes 638,247 105,360 Common stock underlying options 166,505 202,246 Common stock underlying warrants 780,935 516,748 Total common stock equivalents 1,585,687 824,354

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2020
Leases [Abstract]
Schedule of Future Minimum Lease Payments	Future minimum lease payments are as follows for the years ended December 31: 2021 $ 962 962

Company Background (Details Nar

Company Background (Details Narrative) - USD ($)	Jan. 11, 2021	Aug. 14, 2019	Dec. 31, 2020	Dec. 31, 2019
Net losses			$ (5,055,507)	$ (5,093,037)
Accumulated deficit			(72,091,862)	$ (67,036,355)
Proceeds from issuance of debt securities			$ 2,515,300
Proceeds from issuance of common stock and warrants		$ 15,000,000
Preferred Stock [Member] | Private Placement [Member] | Subsequent Event [Member]
Proceeds from sale of preferred stock	$ 50,000
Preferred Stock [Member] | Private Placement [Member] | Maximum [Member] | Subsequent Event [Member]
Aggregate amount of shares issued	$ 10,000,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash equivalents
Federal deposit insurance	0	0
Accounts receivable, net		205,768
Allowance for accounts receivable
Inventory reserves
Payment of stock issuance costs	255,271
Shipping and handling costs	11,310	19,999
Sales taxes	3,045	3,018
Research and development costs	136,780	315,994
Advertising expenses	27,366	161,468
Unrecognized tax benefit
Maximum [Member]
Federal deposit insurance	$ 250,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Revenues Disaggregated by Revenue Source and Geographical Location (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Total revenue	$ 538,946	$ 710,949
United States [Member]
Total revenue	528,574	705,694
Hong Kong [Member]
Total revenue	$ 10,372	$ 5,255

Inventories (Details Narrative)

Inventories (Details Narrative) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Inventory, finished goods	$ 227,597	$ 407,756

Inventories - Schedule of Inven

Inventories - Schedule of Inventories (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 759,400	$ 763,800
Finished goods	234,919	414,031
Total inventories	$ 994,319	$ 1,177,831

Intangible Assets, Net (Details

Intangible Assets, Net (Details Narrative)	12 Months Ended
	Dec. 31, 2020USD ($)Vehicle	Dec. 31, 2019USD ($)
Patent, amortization period	15 years
Amortization expense | $	$ 34,519	$ 39,569
Patents, units	28
Patents expiration date	Patents will expire between 2023 and 2028
Number of patent application pending	4
Number of patent application pending, description	The Company also has four patents pending to extend patent coverage in the U.S. and outside the U.S. to 2039-2041.
United States [Member]
Patents, units	13
Outside the U.S. [Member]
Patents, units	15

Intangible Assets, Net - Schedu

Intangible Assets, Net - Schedule of Intangible Assets, Net (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 499,106	$ 614,003
Less accumulated amortization	(256,742)	(332,081)
Patents, Total	242,364	281,922
Patents pending	60,047	138,451
Total intangible assets, net	$ 302,411	$ 420,373

Accrued Separation Costs (Detai

Accrued Separation Costs (Details Narrative)	Aug. 09, 2016USD ($)
Separation Agreement [Member]
Accrued compensation expenses	$ 118,635

Accrued Separation Costs - Sche

Accrued Separation Costs - Schedule of Accrued Payroll and Payroll Related Expenses (Details)	12 Months Ended
	Dec. 31, 2020USD ($)
Payables and Accruals [Abstract]
2021	$ 12,000
2022	12,000
2023	18,000
2024	18,000
2025	23,635
Accrued Separation Costs Gross	83,635
Less current portion	(12,000)
Accrued Separation Costs Net	$ 71,635

Related Party Notes Payable (De

Related Party Notes Payable (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Interest charges	$ 190,268	$ 147,605
Notes Payable [Member]
Accrued and payable	$ 116,826	$ 47,413

Related Party Notes Payable - S

Related Party Notes Payable - Schedule of Related Party Notes Payable (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Total related party notes payable	$ 1,769,000	$ 1,575,000
Less current portion	(769,000)	(575,000)
Long term notes payable	1,000,000	1,000,000
Inventory Financing [Member]
Total related party notes payable	1,000,000	1,000,000
Officer Loan [Member]
Total related party notes payable	75,000	75,000
Promissory Note [Member]
Total related party notes payable	500,000	500,000
Promissory Note [Member]
Total related party notes payable
Promissory Note [Member]
Total related party notes payable	94,000
Promissory Note [Member]
Total related party notes payable	$ 100,000

Related Party Notes Payable -_2

Related Party Notes Payable - Schedule of Related Party Notes Payable (Details) (Parenthetical) - USD ($)	Dec. 30, 2020	Nov. 06, 2020	Jun. 29, 2020	Jun. 26, 2019	May 20, 2019	Jan. 11, 2019	Jul. 14, 2020	Jul. 10, 2019
Debt instrument, interest rate							12.00%
Inventory Financing [Member]
Line of credit						$ 1,000,000
Line of credit facility, interest rate						12.00%
Inventory Financing [Member] | Minimum [Member]
Ownership percentage						5.00%
Officer Loan [Member]
Debt instrument description				On June 26, 2019, the Company borrowed $75,000 from the Chief Executive Officer of the Company. This note accrues interest at the rate of 4.5% per annum, payable at maturity, is unsecured, and was originally due August 26, 2019, but the maturity date was extended to June 30, 2021.
Officer Loan [Member] | Chief Executive Officer [Member]
Loan borrowed				$ 75,000
Debt instrument, interest rate				4.50%
Promissory Note [Member]
Loan borrowed								$ 100,000
Debt instrument description					This note accrues interest at the rate of 12% per annum, payable at maturity, is unsecured, and was originally due August 20, 2019, but the maturity date was extended to June 30, 2021.
Debt instrument, interest rate								12.00%
Note payable					$ 400,000
Promissory Note [Member] | Minimum [Member]
Ownership percentage					5.00%
Promissory Note [Member]
Ownership percentage			5.00%
Debt instrument description			This note accrued interest at the rate of 12% per annum, payable at maturity, was unsecured, and was originally due September 30, 2020, but the maturity date was extended to October 15, 2020. This note was fully repaid on October 8, 2020.
Debt instrument, interest rate			12.00%
Note payable			$ 25,000
Promissory Note [Member]
Ownership percentage		5.00%
Debt instrument description		This note accrued an issuance fee of $4,000 and a one-time fixed interest charge upon issuance of $2,000, payable at maturity, is unsecured, and was originally due December 6, 2020, but the maturity date was extended to June 30, 2021.
Note payable		$ 94,000
Issuance fee		4,000
One-time fixed interest charges		$ 2,000
Promissory Note [Member]
Ownership percentage	5.00%
Debt instrument description	This note accrues interest at the rate of 12% per annum, is unsecured, and was originally due March 30, 2021, but the maturity date was extended to June 30, 2021. Interest was originally payable monthly but was amended on January 1, 2021, to be payable at maturity.
Debt instrument, interest rate	12.00%
Note payable	$ 100,000

Related Party Notes Payable -_3

Related Party Notes Payable - Schedule of Related Party Future Maturities of Notes Payable (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Total	$ 1,300,000	$ 1,050,000
Related Party Notes Payable [Member]
2021	769,000
2022	1,000,000
Total	$ 1,769,000

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	Jul. 14, 2020	Apr. 22, 2020	Dec. 31, 2020	Dec. 31, 2019
Note payable	$ 25,000
Debt instrument, interest rate	12.00%
Debt instrument, maturity date	Jul. 31, 2020
Interest charges			$ 190,268	$ 147,605
Note Payable [Member]
Interest charges			1,606
Accrued and payable			1,466
Paycheck Protection Program [Member] | Lender [Member]
Proceeds from loan		$ 211,300
Economic Injury Disaster Loan [Member] | Note Payable [Member]
Proceeds from advance			$ 10,000

Related Party Convertible Not_3

Related Party Convertible Notes Payable (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Feb. 29, 2020	Dec. 31, 2020	Dec. 31, 2019
Original issue discount		$ 104,347	$ 82,608
Interest charges incurred		190,268	147,605
Related Party Convertible Note Payable [Member]
Original issue discount		490,658
Interest expense		478,072
Accumulated amortization		420,606
Gain on convertible notes	$ 258,903
Interest charges incurred		102,905	35,132
Interest accrued and payable		$ 10,024	$ 8,205

Related Party Convertible Not_4

Related Party Convertible Notes Payable - Schedule of Related Party Convertible Notes Payable (Details) - USD ($)	Dec. 31, 2020	Sep. 17, 2020	Dec. 31, 2019	Oct. 16, 2019	Jul. 19, 2019
Total notes payable	$ 1,404,347		$ 1,132,608
Less original issue discounts	(104,347)		(82,608)
Total	1,300,000		1,050,000
Less discounts for conversion rights, beneficial conversion features, and detachable warrants	(386,310)		(693,316)
Plus amortization of discounts	420,606		295,037
Total related party convertible notes payable, net	1,334,296		651,721
Convertible Note 2019 - 02 [Member]
Total notes payable	815,217		815,217
Less original issue discounts					$ (65,217)
Convertible Note 2019 - 07 [Member]
Total notes payable	217,391		217,391
Less original issue discounts				$ (17,391)
Officers Convertible Note [Member]
Total notes payable	100,000		100,000
Convertible Note 2020 - 11 [Member]
Total notes payable	271,739
Less original issue discounts		$ (21,739)
Convertible Note 2020 - 16 [Member]
Total notes payable

Related Party Convertible Not_5

Related Party Convertible Notes Payable - Schedule of Related Party Convertible Notes Payable (Details) (Parenthetical)	Dec. 17, 2020USD ($)shares	Sep. 17, 2020USD ($)$ / sharesshares	Jul. 14, 2020	Nov. 15, 2019USD ($)$ / shares	Oct. 16, 2019USD ($)$ / sharesshares	Jul. 19, 2019USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / shares	Dec. 31, 2019USD ($)$ / shares
Original issue discount							$ 104,347	$ 82,608
Debt instrument, interest rate			12.00%
Debt instrument, maturity date			Jul. 31, 2020
Convertible Note 2019 - 02 [Member]
Convertible notes payable issued						$ 815,217
Original issue discount						65,217
Exchange of convertible notes payable						$ 750,000
Debt instrument, interest rate						8.00%
Debt instrument, maturity date						Jun. 30, 2020
Debt instrument, conversion price | $ / shares						$ 24	$ 4.27	$ 14
Debt instrument, discount offering price percentage						0.25
Warrants price per share | $ / shares							$ 4.27	$ 14
Convertible Note 2019 - 02 [Member] | Detachable Warrant [Member]
Warrants to purchase common stock | shares						7,500
Warrants price per share | $ / shares						$ 24
Debt instrument beneficial conversion feature							$ 234,300	$ 582,533
Convertible Note 2019 - 02 [Member] | Minimum [Member]
Convertible notes payable issued						$ 5,000,000
Convertible Note 2019 - 02 [Member] | Extended Maturity [Member]
Debt instrument, maturity date						Jun. 30, 2021
Convertible Note 2019 - 07 [Member]
Convertible notes payable issued					$ 217,391
Original issue discount					17,391
Exchange of convertible notes payable					$ 200,000
Debt instrument, interest rate					8.00%
Debt instrument, maturity date					Jun. 30, 2020
Debt instrument, conversion price | $ / shares					$ 24		$ 4.27	$ 14
Debt instrument, discount offering price percentage					0.25
Warrants price per share | $ / shares							$ 4.27	$ 14
Debt instrument beneficial conversion feature							$ 63,060	$ 110,783
Convertible Note 2019 - 07 [Member] | Detachable Warrant [Member]
Warrants to purchase common stock | shares					2,000
Warrants price per share | $ / shares					$ 24
Convertible Note 2019 - 07 [Member] | Minimum [Member]
Convertible notes payable issued					$ 5,000,000
Convertible Note 2019 - 07 [Member] | Extended Maturity [Member]
Debt instrument, maturity date					Jun. 30, 2021
Officer Convertible Note [Member]
Convertible notes payable issued				$ 100,000
Debt instrument, interest rate				14.00%
Debt instrument, maturity date				Jun. 30, 2020
Debt instrument, conversion price | $ / shares				$ 20
Officer Convertible Note [Member] | Extended Maturity [Member]
Debt instrument, maturity date				Jun. 30, 2021
Convertible Note 2020 - 11 [Member]
Convertible notes payable issued		$ 217,391
Original issue discount		21,739
Exchange of convertible notes payable		$ 250,000
Debt instrument, interest rate		8.00%
Debt instrument, maturity date		Jun. 30, 2021
Debt instrument, conversion price | $ / shares		$ 4.50
Debt instrument, discount offering price percentage		0.25
Debt instrument beneficial conversion feature							$ 88,950
Convertible Note 2020 - 11 [Member] | Detachable Warrant [Member]
Warrants to purchase common stock | shares		13,333
Warrants price per share | $ / shares		$ 4.50
Convertible Note 2020 - 11 [Member] | Minimum [Member]
Convertible notes payable issued		$ 5,000,000
Convertible Note 2020 - 16 [Member]
Convertible notes payable issued	$ 90,000
Debt instrument, interest rate	4.00%
Debt instrument, maturity date	Dec. 31, 2021
Debt instrument converted into shares of common stock | shares	18,000

Related Party Convertible Not_6

Related Party Convertible Notes Payable - Schedule of Related Party Future Maturities of Convertible Notes Payable (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Total	$ 1,300,000	$ 1,050,000
Related Party Convertible Note [Member]
2021	1,404,347
Total	$ 1,404,347

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Narrative) - USD ($)	1 Months Ended		12 Months Ended
	Sep. 30, 2020	Feb. 29, 2020	Dec. 31, 2020	Dec. 31, 2019
Original issue discount			$ 1,841,388	$ 417,001
Gain on convertible notes	$ 40,133	$ 95,888	394,924
Interest charges incurred			190,268	147,605
Convertible Note Payable [Member]
Original issue discount			1,169,372
Interest expense			1,363,316	121,964
Accumulated amortization			802,313
Interest charges incurred			142,227	17,877
Interest accrued and payable			$ 67,648	$ 13,114

Convertible Notes Payable - Sch

Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Total notes payable	$ 1,404,347	$ 1,132,608
Plus amortization of discounts	(420,606)	(295,037)
Convertible Note 2019 - 01 [Member]
Total notes payable		150,000
Convertible Note 2019 - 03 [Member]
Total notes payable	108,696	108,696
Convertible Note 2019 - 04 [Member]
Total notes payable	54,348	54,348
Convertible Note 2019 - 05 [Member]
Total notes payable	27,174	27,174
Convertible Note 2019 - 06 [Member]
Total notes payable	27,174	27,174
Convertible Note 2019 - 08 [Member]
Total notes payable	108,696	108,696
Convertible Note 2019 - 09 [Member]
Total notes payable	27,174	27,174
Convertible Note 2019 - 10 [Member]
Total notes payable	16,304	16,304
Convertible Note 2020 - 01 [Member]
Total notes payable	10,870
Convertible Note 2020 - 02 [Member]
Total notes payable	133,272
Convertible Note 2020 - 03 [Member]
Total notes payable	52,632
Convertible Note 2020 - 04 [Member]
Total notes payable
Convertible Note 2020 - 05 [Member]
Total notes payable	260,000
Convertible Note 2020 - 06 [Member]
Total notes payable	500,000
Convertible Note 2020 - 07 [Member]
Total notes payable	100,000
Convertible Note 2020 - 08 [Member]
Total notes payable	25,000
Convertible Note 2020 - 09 [Member]
Total notes payable	100,000
Convertible Note 2020 - 10 [Member]
Total notes payable	15,000
Convertible Note 2020 - 12 [Member]
Total notes payable	25,000
Convertible Note 2020 - 13 [Member]
Total notes payable	108,696
Convertible Note 2020 - 14 [Member]
Total notes payable	60,000
Convertible Note 2020 - 15 [Member]
Total notes payable	20,000
Convertible Note 2020 - 17 [Member]
Total notes payable	55,556
Convertible Note Payable [Member]
Total notes payable	1,835,592	519,566
Less original issue discounts	(107,320)	(29,566)
Convertible notes payable, net	1,728,272	490,000
Less discounts for conversion rights, beneficial conversion features, debt issuance costs, and detachable warrants	(1,062,054)	(253,675)
Plus amortization of discounts	802,313	121,964
Total convertible notes payable, net	$ 1,468,531	358,289
Convertible Note 2020 - 01 [Member]
Total notes payable

Convertible Notes Payable - S_2

Convertible Notes Payable - Schedule of Convertible Notes Payable (Details) (Parenthetical) - USD ($)

May 14, 2021

Apr. 22, 2021

Mar. 30, 2021

Mar. 12, 2021

Feb. 26, 2021

Feb. 22, 2021

Feb. 12, 2021

Jan. 28, 2021

Dec. 28, 2020

Dec. 11, 2020

Dec. 01, 2020

Nov. 13, 2020

Nov. 10, 2020

Nov. 09, 2020

Oct. 08, 2020

Sep. 28, 2020

Sep. 22, 2020

Sep. 18, 2020

Sep. 08, 2020

Aug. 07, 2020

Jul. 30, 2020

Jul. 21, 2020

Jul. 14, 2020

May 14, 2020

Mar. 16, 2020

Feb. 25, 2020

Jan. 21, 2020

Jan. 06, 2020

Nov. 08, 2019

Oct. 29, 2019

Oct. 23, 2019

Oct. 10, 2019

Oct. 03, 2019

Sep. 25, 2019

Sep. 04, 2019

Apr. 18, 2019

Mar. 29, 2021

Mar. 08, 2021

Feb. 01, 2021

Dec. 31, 2020

Aug. 10, 2020

Mar. 17, 2020

Dec. 31, 2019

Debt instrument, interest rate

12.00%

Debt instrument, maturity date

Jul. 31, 2020

Original issue discount

$ 104,347

$ 82,608

Inventory

994,319

$ 1,177,831

Convertible Note 2019 - 01 [Member]

Convertible notes payable issued

$ 150,000

Debt instrument, interest rate

10.00%

Debt instrument, maturity date

Dec. 31, 2019

Debt instrument maturity date, description

Originally matured on December 31, 2019, which was subsequently extended to March 31, 2020.

Debt instrument, conversion price

$ 24

Adjusted exercise price per share

$ 4.27

$ 14

Additional discount on convertible note

$ 199,012

Convertible Note 2019 - 01 [Member] | Detachable Warrant [Member]

Warrants to purchase common stock

2,500

Warrants price per share

$ 40

Convertible Note 2019 - 03 [Member]

Convertible notes payable issued

$ 108,696

Debt instrument, interest rate

8.00%

Debt instrument, maturity date

Jun. 30, 2020

Debt instrument, conversion price

$ 24

Original issue discount

$ 8,696

Exchange of convertible notes payable

$ 100,000

Debt instrument, amortized period

24 months

Convertible Note 2019 - 03 [Member] | Extended Maturity [Member]

Debt instrument, maturity date

Jun. 30, 2021

Convertible Note 2019 - 03 [Member] | Detachable Warrant [Member]

Warrants to purchase common stock

1,000

Warrants price per share

$ 24

Additional discount on convertible note

$ 18,326

Convertible Note 2019 - 04 [Member]

Convertible notes payable issued

$ 54,348

Debt instrument, interest rate

8.00%

Debt instrument, maturity date

Jun. 30, 2020

Debt instrument, conversion price

$ 24

Original issue discount

$ 4,348

Exchange of convertible notes payable

$ 50,000

Debt instrument, amortized period

36 months

Convertible Note 2019 - 04 [Member] | Extended Maturity [Member]

Debt instrument, maturity date

Jun. 30, 2021

Convertible Note 2019 - 04 [Member] | Detachable Warrant [Member]

Warrants to purchase common stock

500

Warrants price per share

$ 24

Additional discount on convertible note

$ 4,190

Convertible Note 2019 - 05 [Member]

Convertible notes payable issued

$ 27,174

Debt instrument, interest rate

8.00%

Debt instrument, maturity date

Jun. 30, 2020

Debt instrument, conversion price

$ 24

Original issue discount

$ 2,174

Exchange of convertible notes payable

$ 25,000

Debt instrument, amortized period

36 months

Convertible Note 2019 - 05 [Member] | Extended Maturity [Member]

Debt instrument, maturity date

Jun. 30, 2021

Convertible Note 2019 - 05 [Member] | Detachable Warrant [Member]

Warrants to purchase common stock

250

Warrants price per share

$ 24

Additional discount on convertible note

$ 2,705

Convertible Note 2019 - 06 [Member]

Convertible notes payable issued

$ 27,174

Debt instrument, interest rate

8.00%

Debt instrument, maturity date

Jun. 30, 2020

Debt instrument, conversion price

$ 24

Original issue discount

$ 2,174

Exchange of convertible notes payable

$ 25,000

Debt instrument, amortized period

36 months

Convertible Note 2019 - 06 [Member] | Extended Maturity [Member]

Debt instrument, maturity date

Jun. 30, 2021

Convertible Note 2019 - 06 [Member] | Detachable Warrant [Member]

Warrants to purchase common stock

250

Warrants price per share

$ 24

Additional discount on convertible note

$ 2,505

Convertible Note 2019 - 08 [Member]

Convertible notes payable issued

$ 108,696

Debt instrument, interest rate

8.00%

Debt instrument, maturity date

Jun. 30, 2020

Debt instrument, conversion price

$ 24

Original issue discount

$ 8,696

Exchange of convertible notes payable

$ 100,000

Debt instrument, amortized period

36 months

Convertible Note 2019 - 08 [Member] | Extended Maturity [Member]

Debt instrument, maturity date

Jun. 30, 2021

Convertible Note 2019 - 08 [Member] | Detachable Warrant [Member]

Additional discount on convertible note

$ 21,363

Convertible Note 2019 - 08 [Member] | Detachable Warrant One [Member]

Warrants to purchase common stock

1,250

Warrants price per share

$ 30

Convertible Note 2019 - 08 [Member] | Detachable Warrant Two [Member]

Warrants to purchase common stock

1,250

Warrants price per share

$ 40

Convertible Note 2019 - 09 [Member]

Convertible notes payable issued

$ 27,174

Debt instrument, interest rate

8.00%

Debt instrument, maturity date

Jun. 30, 2020

Debt instrument, conversion price

$ 24

Original issue discount

$ 2,174

Exchange of convertible notes payable

$ 25,000

Debt instrument, amortized period

36 months

Convertible Note 2019 - 09 [Member] | Extended Maturity [Member]

Debt instrument, maturity date

Jun. 30, 2021

Convertible Note 2019 - 09 [Member] | Detachable Warrant [Member]

Warrants to purchase common stock

250

Warrants price per share

$ 24

Additional discount on convertible note

$ 2,295

Convertible Note 2019 - 10 [Member]

Convertible notes payable issued

$ 16,304

Debt instrument, interest rate

8.00%

Debt instrument, maturity date

Jun. 30, 2020

Debt instrument, conversion price

$ 14

Original issue discount

$ 1,304

Exchange of convertible notes payable

$ 15,000

Debt instrument, amortized period

36 months

Convertible Note 2019 - 10 [Member] | Extended Maturity [Member]

Debt instrument, maturity date

Jun. 30, 2021

Convertible Note 2019 - 10 [Member] | Detachable Warrant [Member]

Warrants to purchase common stock

150

Warrants price per share

$ 14

Additional discount on convertible note

$ 3,279

Convertible Note 2020 - 01 [Member]

Convertible notes payable issued

$ 10,870

Debt instrument, interest rate

8.00%

Debt instrument, maturity date

Jun. 30, 2020

Debt instrument, conversion price

$ 10

Original issue discount

$ 870

Exchange of convertible notes payable

$ 10,000

Debt instrument, amortized period

36 months

Convertible Note 2020 - 01 [Member] | Extended Maturity [Member]

Debt instrument, maturity date

Jun. 30, 2021

Convertible Note 2020 - 01 [Member] | Detachable Warrant [Member]

Warrants to purchase common stock

100

Warrants price per share

$ 10

Additional discount on convertible note

$ 793

Convertible Note 2020 - 02 [Member]

Convertible notes payable issued

$ 262,500

Debt instrument, interest rate

10.00%

Debt instrument, maturity date

Jun. 1, 2020

Debt instrument, conversion price

$ 4.27

Original issue discount

$ 12,500

Exchange of convertible notes payable

$ 250,000

Common stock issued as commitment fee

5,855

Number of common stock shares issued

6,250

Extension fee

$ 25,000

Convertible Note 2020 - 02 [Member] | Holder [Member]

Inventory

$ 200,000

Accrued and unpaid interest

32,003

Debt instrument, principal payment

129,228

Premium principal repayment

$ 38,769

Convertible Note 2020 - 02 [Member] | Holder [Member] | Subsequent Event [Member]

Inventory

$ 20,000

$ 10,000

$ 100,000

Convertible Note 2020 - 02 [Member] | Extended Maturity [Member]

Debt instrument, maturity date

Feb. 28, 2021

Convertible Note 2020 - 02 [Member] | Detachable Warrant [Member]

Additional discount on convertible note

$ 110,247

25,000

Convertible Note 2020 - 03 [Member]

Convertible notes payable issued

$ 52,632

Debt instrument, interest rate

8.00%

Debt instrument, maturity date

Jun. 30, 2020

Debt instrument, conversion price

$ 7.50

Original issue discount

$ 2,632

Exchange of convertible notes payable

$ 50,000

Debt instrument, amortized period

36 months

Debt instrument, discount offering price percentage

25.00%

Convertible Note 2020 - 03 [Member] | Minimum [Member]

Convertible notes payable issued

$ 5,000,000

Convertible Note 2020 - 03 [Member] | Extended Maturity [Member]

Debt instrument, maturity date

Jun. 30, 2021

Convertible Note 2020 - 03 [Member] | Detachable Warrant [Member]

Warrants to purchase common stock

500

Warrants price per share

$ 7.50

Additional discount on convertible note

$ 1,985

Convertible Note 2020 - 04 [Member]

Convertible notes payable issued

$ 250,000

Debt instrument, interest rate

10.00%

Debt instrument, maturity date

Sep. 16, 2020

Debt instrument maturity date, description

This note was fully repaid as of May 14, 2020

Debt instrument, conversion price

$ 4.50

Original issue discount

$ 20,000

Exchange of convertible notes payable

$ 230,000

Common stock issued as commitment fee

5,000

Debt issuance cost

$ 27,777

Debt instrument, description

fully repaid within 6 months of issuance

Legal expenses

$ 5,000

Convertible Note 2020 - 04 [Member] | Detachable Warrant [Member]

Additional discount on convertible note

343,854

Convertible Note 2020 - 05 [Member]

Convertible notes payable issued

$ 250,000

Debt instrument, interest rate

10.00%

Debt instrument, maturity date

Sep. 16, 2020

Debt instrument, conversion price

$ 4.50

Original issue discount

$ 20,000

Exchange of convertible notes payable

$ 230,000

Common stock issued as commitment fee

5,000

Legal expenses

$ 5,000

Number of common stock shares issued

27,777

Convertible Note 2020 - 05 [Member] | Increased Principal as a Consideration for Extension [Member]

Convertible notes payable issued

$ 10,000

Convertible Note 2020 - 05 [Member] | Amount Paid as Consideration for Extension [Member]

Extension fee

$ 7,500

$ 7,500

Convertible Note 2020 - 05 [Member] | Subsequent Event [Member] | Amount Paid as Consideration for Extension [Member]

Extension fee

$ 7,500

$ 7,500

$ 7,500

$ 7,500

Convertible Note 2020 - 05 [Member] | Extended Maturity [Member]

Debt instrument, maturity date

May 31, 2021

Convertible Note 2020 - 05 [Member] | Detachable Warrant [Member]

Additional discount on convertible note

$ 343,854

Convertible Note 2020 - 05 One [Member]

Convertible notes payable issued

$ 500,000

Debt instrument, interest rate

10.00%

Debt instrument, maturity date

May 14, 2021

Debt instrument, conversion price

$ 9.75

$ 4.50

Additional discount on convertible note

$ 280,158

Original issue discount

$ 40,000

Exchange of convertible notes payable

460,000

Legal expenses

$ 10,000

Convertible Note 2020 - 05 One [Member] | Amount Paid as Consideration for Extension [Member]

Extension fee

$ 25,000

$ 25,000

Convertible Note 2020 - 05 One [Member] | Shares issued as Commitment Fee [Member]

Number of common stock shares issued

10,000

Convertible Note 2020 - 05 One [Member] | Subsequent Event [Member] | Amount Paid as Additional Consideration for Extension [Member]

Extension fee

$ 12,500

$ 12,500

$ 12,500

$ 12,500

$ 12,500

Convertible Note 2020 - 07 [Member]

Convertible notes payable issued

$ 100,000

Debt instrument, interest rate

8.00%

Debt instrument, maturity date

Jun. 30, 2021

Debt instrument, conversion price

$ 5

Debt instrument, amortized period

36 months

Debt instrument, discount offering price percentage

25.00%

Convertible Note 2020 - 07 [Member] | Minimum [Member]

Convertible notes payable issued

$ 5,000,000

Debt instrument, conversion price

$ 5

Convertible Note 2020 - 07 [Member] | Warrant [Member]

Warrants to purchase common stock

20,000

Warrants price per share

$ 7.50

Warrants term

5 years

Warrants recognition

$ 105,800

Convertible Note 2020 - 07 [Member] | Warrant [Member]

Warrants to purchase common stock

20,000

Warrants price per share

$ 10

Convertible Note 2020 - 08 [Member]

Convertible notes payable issued

$ 25,000

Debt instrument, interest rate

12.00%

Debt instrument, maturity date

Sep. 30, 2020

Debt instrument, conversion price

$ 5

Debt instrument, amortized period

24 months

Convertible Note 2020 - 08 [Member] | Minimum [Member]

Convertible notes payable issued

$ 5,000,000

Convertible Note 2020 - 08 [Member] | Extended Maturity [Member]

Debt instrument, maturity date

Jun. 30, 2021

Convertible Note 2020 - 08 [Member] | Warrant [Member]

Warrants to purchase common stock

250

Warrants price per share

$ 5

Warrants term

5 years

Warrants recognition

$ 953

Convertible Note 2020 - 09 [Member]

Convertible notes payable issued

$ 100,000

Debt instrument, interest rate

8.00%

Debt instrument, maturity date

Jul. 31, 2021

Debt instrument, conversion price

$ 5

Debt instrument, amortized period

24 months

Convertible Note 2020 - 09 [Member] | Warrant [Member]

Warrants to purchase common stock

20,000

Warrants price per share

$ 7.50

Warrants term

5 years

Warrants recognition

$ 106,000

Convertible Note 2020 - 09 [Member] | Warrant [Member]

Warrants to purchase common stock

20,000

Warrants price per share

$ 10

Convertible Note 2020 - 10 [Member]

Convertible notes payable issued

$ 15,000

Debt instrument, interest rate

8.00%

Debt instrument, maturity date

Jun. 30, 2021

Debt instrument, conversion price

$ 4.50

Debt instrument, amortized period

36 months

Convertible Note 2020 - 10 [Member] | Warrant [Member]

Warrants to purchase common stock

2,000

Warrants price per share

$ 7.50

Warrants term

5 years

Warrants recognition

$ 5,300

Convertible Note 2020 - 12 [Member]

Convertible notes payable issued

$ 25,000

Debt instrument, interest rate

8.00%

Debt instrument, maturity date

Jun. 30, 2021

Debt instrument, conversion price

$ 4.50

Debt instrument, amortized period

36 months

Convertible Note 2020 - 12 [Member] | Warrant [Member]

Warrants to purchase common stock

5,555

Warrants price per share

$ 4.50

Warrants term

5 years

Warrants recognition

$ 11,499

Convertible Note 2020 - 13 [Member]

Convertible notes payable issued

$ 108,696

Debt instrument, interest rate

8.00%

Debt instrument, maturity date

Jun. 30, 2021

Debt instrument, conversion price

$ 4.50

Original issue discount

$ 8,696

Exchange of convertible notes payable

$ 100,000

Debt instrument, amortized period

36 months

Convertible Note 2020 - 13 [Member] | Warrant [Member]

Warrants to purchase common stock

24,155

Warrants price per share

$ 4.50

Warrants term

5 years

Warrants recognition

$ 50,001

Convertible Note 2020 - 14 [Member]

Convertible notes payable issued

$ 60,000

Debt instrument, interest rate

8.00%

Debt instrument, maturity date

Sep. 30, 2021

Debt instrument, conversion price

$ 4.50

Debt instrument, amortized period

36 months

Convertible Note 2020 - 14 [Member] | Warrant [Member]

Warrants to purchase common stock

13,333

Warrants price per share

$ 4.50

Warrants term

5 years

Warrants recognition

$ 27,599

Convertible Note 2020 - 15 [Member]

Convertible notes payable issued

$ 20,000

Debt instrument, interest rate

8.00%

Debt instrument, maturity date

Sep. 30, 2021

Debt instrument, conversion price

$ 4.50

Debt instrument, amortized period

36 months

Convertible Note 2020 - 15 [Member] | Warrant [Member]

Warrants to purchase common stock

4,444

Warrants price per share

$ 4.50

Warrants term

5 years

Warrants recognition

$ 9,199

Convertible Note 2020 - 17 [Member]

Convertible notes payable issued

$ 55,556

Debt instrument, interest rate

8.00%

Debt instrument, maturity date

Dec. 31, 2021

Debt instrument, conversion price

$ 5

Original issue discount

$ 5,556

Exchange of convertible notes payable

$ 50,000

Debt instrument, amortized period

36 months

Convertible Note 2020 - 17 [Member] | Warrant [Member]

Original issue discount

$ 15,000

Exchange of convertible notes payable

$ 5

Warrants term

5 years

Warrants recognition

$ 14,250

Convertible Notes Payable - S_3

Convertible Notes Payable - Schedule of Future Maturities of Convertible Notes Payable (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Total	$ 1,300,000	$ 1,050,000
Convertible Note Payable [Member]
2021	1,835,592
Total	$ 1,835,592

Derivative Financial Instrume_3

Derivative Financial Instruments - Schedule of Fair Value Assumptions Related to Option Issued (Details)	12 Months Ended
	Dec. 31, 2020USD ($)Vehicle	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Derivative liabilities | $	$ 235,165	$ 827,314
Convertible Note Payable [Member]
Derivative liabilities | $	(222,707)	356,314
Convertible Note Payable [Member] | Fair Value, Inputs, Level 1 [Member]
Derivative liabilities | $
Convertible Note Payable [Member] | Fair Value, Inputs, Level 2 [Member]
Derivative liabilities | $
Convertible Note Payable [Member] | Fair Value, Inputs, Level 3 [Member]
Derivative liabilities | $	$ 235,165	$ 827,314
Convertible Note Payable [Member] | Expected Dividend Yield [Member]
Derivative liabilities, measurement input | Vehicle	0
Convertible Note Payable [Member] | Risk Free Interest Rate [Member] | Minimum [Member]
Derivative liabilities, measurement input | Vehicle	0.10
Convertible Note Payable [Member] | Risk Free Interest Rate [Member] | Maximum [Member]
Derivative liabilities, measurement input | Vehicle	1.43
Convertible Note Payable [Member] | Volatility [Member] | Minimum [Member]
Derivative liabilities, measurement input | Vehicle	147
Convertible Note Payable [Member] | Volatility [Member] | Maximum [Member]
Derivative liabilities, measurement input | Vehicle	190
Convertible Note Payable [Member] | Expected Term [Member]
Derivative liabilities, expected term	1 year

Derivative Financial Instrume_4

Derivative Financial Instruments - Schedule of Recognized Derivative Liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative liabilities as of beginning	$ 827,314
Valuation upon issuance	433,672	323,675
Revaluation upon modification	(344,137)	147,325
Change in fair value	(222,707)	356,314
Elimination upon extinguishment	(458,977)
Derivative liabilities as of ending	$ 235,165	$ 827,314

Stockholders' Deficit (Details

Stockholders' Deficit (Details Narrative) - USD ($)

Mar. 29, 2021

Jan. 13, 2021

Jan. 11, 2021

Dec. 17, 2020

Jan. 15, 2020

Dec. 31, 2020

Dec. 31, 2019

Mar. 31, 2021

Mar. 26, 2021

Jan. 29, 2021

Jan. 27, 2021

Jan. 19, 2021

Reverse stock split

200-for-1 reverse stock split

Sold securities in a self-directed offering, aggregate amount

$ 245,000

Common stock, shares outstanding

794,183

687,564

Convertible Note Payable [Member]

Debt instrument principal amount

$ 90,000

Self-Directed Stock Issuance [Member] | Existing Stockholders [Member]

Sold securities in a self-directed offering, aggregate amount

$ 245,000

Issuance of stock per share

$ 60

Sale of stock, description of transaction

Each $60 unit consisted of 2 shares of restricted common stock (8,169 shares) and a five-year warrant to purchase 1 share of restricted common stock (4,085 warrant shares) at $40 per share.

Number of restricted common stock

8,169

Warrants to purchase of common stock shares

4,085

Warrants term

5 years

Self-Directed Stock Issuance [Member] | Existing Stockholders [Member] | Restricted Common Stock [Member]

Issuance of stock per share

$ 60

Restricted Common Stock [Member]

Stock issued during period shares

18,000

Subsequent Event [Member] | Convertible Note Payable [Member]

Stock issued during period shares

27,777

27,777

Debt instrument principal amount

$ 250,000

$ 250,000

$ 262,500

$ 100,000

$ 262,500

$ 55,556

$ 500,000

Series A Preferred Stock [Member] | Subsequent Event [Member]

Stock issued during period shares

2,000

Aggregate purchase price of shares

$ 50,000

Stock Grants (Details Narrative

Stock Grants (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Number of shares granted during period
Stock-based compensation expense	$ 257,500	$ 341,938
Holder [Member]
Consideration for commitment fees, shares	27,777
Issuance of debt cancelled shares	27,777
Extension fees	$ 6,250
Restricted Common Stock [Member] | Directors [Member]
Number of shares granted during period	28,737	11,054
Stock-based compensation expense	$ 75,000	$ 350,000
Restricted Common Stock [Member] | Consultant [Member]
Number of shares granted during period		750
Stock-based compensation expense		$ 16,650
Restricted Common Stock [Member] | Holder [Member]
Stock issued during period convertible note	81,409

Stock Option Plans (Details Nar

Stock Option Plans (Details Narrative) - shares	Dec. 04, 2018	Feb. 07, 2014	Dec. 31, 2020	Dec. 31, 2019	Jan. 02, 2021	Jan. 02, 2020	Apr. 16, 2015
Options default term			3 years 3 months 4 days	4 years 1 month 6 days
Number of options expired during period			35,741
2014 Equity Compensation Plan [Member]
Number of reserved for future issuance		152,101	279,101			27,000
2014 Equity Compensation Plan [Member] | Common Stock [Member]
Number of reserved for future issuance			310,101
2014 Equity Compensation Plan [Member] | Subsequent Event [Member]
Number of reserved for future issuance					31,000
2014 Equity Compensation Plan [Member] | Majority Stockholders [Member]
Number of reserved for future issuance							75,000
2014 Equity Compensation Plan [Member] | Stockholders [Member]
Number of reserved for future issuance	25,000
Reserved shares description	On December 4, 2018, the stockholders of the Company approved an increase in the shares reserved under this plan by an additional 25,000 shares and authorized the annual increase of the shares reserved under this plan on January 1st of each year, at the discretion of the Board of Directors, by up to such number of shares that is equal to four percent (4%) of the shares of common stock issued and outstanding as of December 31st of the previous calendar year.
2014 Equity Compensation Plan and 2006 Stock Incentive Plan [Member]
Percentage price per share of options granted of fair market value		10.00%
Options default term		10 years
Option vested term		4 years
Number of options expired during period			35,741
2014 Equity Compensation Plan and 2006 Stock Incentive Plan [Member] | Employees [Member] | Maximum [Member]
Percentage price per share of options granted of fair market value		100.00%
2014 Equity Compensation Plan and 2006 Stock Incentive Plan [Member] | 10% Stockholder [Member] | Maximum [Member]
Percentage price per share of options granted of fair market value		110.00%
2014 Equity Compensation Plan and 2006 Stock Incentive Plan [Member] | Employees, Directors, Advisors and Consultants [Member] | Maximum [Member] | Non-statutory Stock Options and Restricted Stock [Member]
Percentage price per share of options granted of fair market value		100.00%

Stock Option Plans - Schedule o

Stock Option Plans - Schedule of Stock Option Activity (Details) - USD ($)	3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2020	Jun. 30, 2020	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Options Outstanding, Beginning balance	202,246	202,246	202,246	202,246	202,537
Options Exercisable, Beginning balance	192,108	192,108	192,108	192,108	185,837
Options, Canceled					(291)
Options, Granted
Options, Exercised
Options, Expired				(35,741)
Options Outstanding, Ending balance				166,505	202,246
Options Exercisable, Ending balance				160,536	192,108
Weighted Average Exercise Price, Outstanding, Beginning balance	$ 80.14	$ 80.14	$ 80.14	$ 80.14	$ 80.13
Weighted Average Exercise Price, Exercisable, Beginning balance	81.32	81.32	81.32	81.32	82.13
Weighted Average Exercise Price, Canceled
Weighted Average Exercise Price, Granted	$ 6	$ 2.25	$ 3	1.70
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired
Weighted Average Exercise Price, Outstanding, Ending balance				85.81	80.14
Weighted Average Exercise Price, Exercisable, Ending balance				$ 87	$ 81.32
Weighted Average Remaining Contractual Term in Years, Outstanding Beginning				3 years 6 months 7 days	4 years 6 months 7 days
Weighted Average Remaining Contractual Term in Years, Exercisable, Beginning				3 years 3 months 4 days	4 years 1 month 6 days
Weighted Average Remaining Contractual Term in Years, Outstanding Ending				3 years 1 month 20 days	3 years 6 months 7 days
Weighted Average Remaining Contractual Term in Years, Exercisable, Ending				2 years 11 months 23 days	3 years 3 months 4 days
Aggregate Intrinsic Value, Outstanding Beginning balance					$ 987,064
Aggregate Intrinsic Value, Exercisable Beginning balance					987,064
Aggregate Intrinsic Value, Outstanding Ending balance
Aggregate Intrinsic Value, Exercisable Ending balance

Stock Option Plans - Schedule_2

Stock Option Plans - Schedule of Non-vested Shares Granted Under Stock Option Plan (Details) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Non-vested, Options Outstanding, Beginning balance	10,138	16,700
Non-vested, Options Granted
Non-vested, Options Vested	(4,169)	(6,271)
Non-vested, Options Canceled		(291)
Non-vested, Options Outstanding, Ending balance	5,969	10,138

Stock Option Plans - Schedule_3

Stock Option Plans - Schedule of Recognized Stock Based Compensation Expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Service provider compensation	$ 98,750	$ 177,500
Employee compensation	158,750	164,438
Total	$ 257,500	$ 341,938

Warrants (Details Narrative)

Warrants (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Discount on convertible notes	$ 104,347	$ 82,608
Stock compensation expense	257,500	341,938
Warrant [Member]
Stock compensation expense	$ 300,000
Warrants expired	85,171	94,577
Convertible Note Warrants [Member]
Warrants to purchase of common stock shares	230,670	16,900
Warrants, term	5 years
Discount on convertible notes	$ 421,399	$ 125,545
Convertible Note Warrants [Member] | Minimum [Member]
Warrant price per share	$ 4.50	$ 14
Convertible Note Warrants [Member] | Maximum [Member]
Warrant price per share	$ 10	$ 40

Warrants - Schedule of Stock Wa

Warrants - Schedule of Stock Warrants Activity (Details) - USD ($)	3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2020	Jun. 30, 2020	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Warrants, Granted	12,756	34,248	25,952	45,732
Warrant [Member]
Warrants, Outstanding, Beginning balance	516,748	516,748	516,748	516,748	590,340
Warrants Exercisable, Beginning balance	516,748	516,748	516,748	516,748	590,340
Warrants, Canceled
Warrants, Granted				349,358	20,985
Warrants, Exercised
Warrants, Expired				(85,171)	(94,577)
Warrants, Outstanding, Ending balance				780,935	516,748
Warrants Exercisable, Ending balance				780,935	516,748
Weighted Average Exercise Price, Outstanding, Beginning	$ 24.60	$ 24.60	$ 24.60	$ 24.60	$ 40.65
Weighted Average Exercise Price, Exercisable, Beginning	$ 24.60	$ 24.60	$ 24.60	24.60	40.65
Weighted Average Exercise Price, Outstanding, Ending				15.47	24.60
Weighted Average Exercise Price, Exercisable, Ending				$ 15.47	$ 24.60
Weighted Average Remaining Contractual Term in Years, Beginning Outstanding				1 year 10 months 10 days	2 years 3 months 26 days
Weighted Average Remaining Contractual Term in Years, Beginning Exercisable				1 year 10 months 10 days	2 years 3 months 26 days
Weighted Average Remaining Contractual Term in Years, Ending Outstanding				3 years 6 months 10 days	1 year 10 months 10 days
Weighted Average Remaining Contractual Term in Years, Ending Exercisable				3 years 6 months 10 days	1 year 10 months 10 days
Aggregate Intrinsic Value, Outstanding, Beginning					$ 7,846,743
Aggregate Intrinsic Value, Exercisable, Beginning					7,846,743
Aggregate Intrinsic Value, Outstanding, Ending
Aggregate Intrinsic Value, Exercisable, Ending

Warrants - Schedule of Fair val

Warrants - Schedule of Fair value of Warrant Valuations (Details) - Warrant [Member] - Vehicle	Dec. 31, 2020	Dec. 31, 2019
Measurement Input, Expected Dividend Rate [Member]
Warrants, measurement input	0	0
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Warrants, measurement input	0.13	1.34
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Warrants, measurement input	1.55	2.37
Measurement Input, Price Volatility [Member] | Minimum [Member]
Warrants, measurement input	143	145
Measurement Input, Price Volatility [Member] | Maximum [Member]
Warrants, measurement input	207	168
Measurement Input, Expected Term [Member] | Minimum [Member]
Warrants term	2 years	2 years
Measurement Input, Expected Term [Member] | Maximum [Member]
Warrants term	5 years	2 years 6 months

Warrants - Schedule of Independ

Warrants - Schedule of Independent Directors Warrants (Details) - $ / shares	3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Mar. 31, 2020	Jun. 30, 2020	Sep. 30, 2020	Dec. 31, 2020
Warrants and Rights Note Disclosure [Abstract]
Warrants	12,756	34,248	25,952	45,732
Warrants exercise price	$ 6	$ 2.25	$ 3	$ 1.70

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Effective tax statutory rate	21.00%	21.00%
Operating loss carryforward	$ 36,410,868
Federal [member]
Operating loss carryforward	$ 46,286,607

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Taxes Rate (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Change in valuation allowance	19.02%	12.80%
Debt instruments	(2.57%)	3.19%
Stock based compensation	2.63%	2.92%
Accrued compensation	2.80%	1.03%
Interest expense	(2.26%)	0.85%
Depreciation and amortization	1.37%	0.16%
Other	0.00%	0.04%
Tax provision (benefit) at Federal statutory rate	(21.00%)	(21.00%)
Effective tax rate	0.00%	0.00%

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Income Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 12,186,945	$ 10,670,455
Accrued compensation	1,341,779	1,211,630
Stock based compensation	175,676	196,809
Credit carryforwards	58,122	58,122
Interest expenses	57,333	57,332
Depreciation and amortization	(155,304)	(208,482)
Debt instruments	(14,944)	(408,144)
Total	13,649,607	11,577,722
Less valuation allowance	(13,649,607)	(11,577,722)
NET DEFERRED TAX ASSETS

Basic and Diluted Net Loss Pe_3

Basic and Diluted Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Earnings Per Share [Abstract]
Net loss (numerator) Basic loss per share, basic	$ (5,055,507)	$ (5,093,037)
Net loss (numerator) Effect of dilutive securities-Common stock options, warrants, and convertible note
Net loss (numerator) Diluted loss per share, diluted	$ (5,055,507)	$ (5,093,037)
Shares (Denominator) Basic loss per shares, basic	744,555	680,152
Shares (Denominator) Effect of dilutive securities-Common stock options, warrants, and convertible note
Shares (Denominator) Diluted loss per shares, diluted	744,555	680,152
Per share amount Basic loss per share, basic	$ (6.79)	$ (7.49)
Per share amount Effect of dilutive securities-Common stock options, warrants, and convertible note
Per share amount Diluted loss per share, diluted	$ (6.79)	$ (7.49)

Basic and Diluted Net Loss Pe_4

Basic and Diluted Net Loss Per Share - Schedule of Shares of Common Stock Equivalents Were Excluded from Computation of Diluted Net Loss Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Total common stock equivalents	1,585,687	824,354
Common Stock Warrants [Member]
Total common stock equivalents	780,935	516,748
Common Stock Convertible Notes [Member]
Total common stock equivalents	638,247	105,360
Common Stock Options [Member]
Total common stock equivalents	166,505	202,246

Leases (Details Narrative)

Leases (Details Narrative) - USD ($)	Aug. 31, 2019	Jan. 31, 2018	Dec. 31, 2020	Dec. 31, 2019	Aug. 13, 2010
Operating lease, right-to-use asset			$ 962	$ 12,488
ASU No. 2016-02 [Member]
Operating lease, right-to-use asset			962	12,488
Operating lease, liabilities			962	12,488
Vehicle Lease Arrangement [Member]
Lease, term		3 years
Total monthly payment	$ 1,002	$ 1,619
Lease expense			15,315	16,174
Office Lease [Member]
Lease, term					45 days
Rent expenses			$ 36,777	$ 37,915

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Lease Payments (Details)	Dec. 31, 2020USD ($)
Leases [Abstract]
2020	$ 962
Future minimum lease payments	$ 962

Commitments (Details Narrative)

Commitments (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Payment for license cost	$ 10,000
Percentage of royalties revenue	2.00%
License payable	$ 20,000	$ 20,000
License expiration date	Feb. 29, 2016
Employee settlement	$ 50,000	$ 50,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Mar. 30, 2021	Mar. 29, 2021	Mar. 26, 2021	Mar. 08, 2021	Feb. 06, 2021	Jan. 28, 2021	Jan. 27, 2021	Jan. 13, 2021	Jan. 11, 2021	Jul. 14, 2020	May 14, 2021	Apr. 22, 2021	Mar. 31, 2021	Mar. 12, 2021	Feb. 26, 2021	Feb. 22, 2021	Feb. 14, 2021	Feb. 01, 2021	Jan. 29, 2021	Jan. 19, 2021	Jan. 01, 2021	Dec. 31, 2020	Dec. 17, 2020	Dec. 31, 2019	Jan. 11, 2019
Debt instrument, maturity date										Jul. 31, 2020
Debt instrument interest rate										12.00%
Inventory																						$ 994,319		$ 1,177,831
Original issue discount																						104,347		82,608
Inventory Financing [Member]
Line of credit																									$ 1,000,000
Convertible Note Payable [Member]
Debt instrument principal amount																							$ 90,000
Convertible note payable																						$ 1,728,272		$ 490,000
Subsequent Event [Member] | Related Party Notes Payable [Member]
Debt instrument principal amount	$ 100,000																				$ 100,000
Debt instrument, maturity date	Jun. 30, 2021
Subsequent Event [Member] | Related Party Convertible Note Payable One [Member]
Debt instrument principal amount																					815,217
Subsequent Event [Member] | Related Party Convertible Note Payable Two [Member]
Debt instrument principal amount																					217,391
Subsequent Event [Member] | Related Party Convertible Note Payable Three [Member]
Debt instrument principal amount																					100,000
Subsequent Event [Member] | Related Party Convertible Note Payable Four [Member]
Debt instrument principal amount																					271,739
Subsequent Event [Member] | Inventory Financing [Member]
Line of credit																					1,000,000
Subsequent Event [Member] | PPP Loan [Member]
Proceeds from loan					$ 211,359
Subsequent Event [Member] | Convertible Note Payable One [Member]
Debt instrument principal amount																					108,696
Convertible note payable						$ 100,000
Debt instrument interest rate						8.00%
Debt instrument, convertible, conversion price						$ 5
Extension fees						$ 7,500											$ 12,500
Subsequent Event [Member] | Convertible Note Payable [Member]
Stock issued during period shares		27,777						27,777
Debt instrument principal amount		$ 250,000	$ 100,000				$ 55,556	$ 250,000					$ 262,500						$ 262,500	$ 500,000
Debt instrument, maturity date		May 25, 2021	Mar. 31, 2022	Mar. 8, 2022		Dec. 31, 2021	Dec. 31, 2021	Feb. 28, 2021
Convertible note payable				$ 150,000
Debt instrument interest rate			8.00%	8.00%			8.00%
Debt instrument, convertible, conversion price				$ 5
Ownership percentage				5.00%
Extension fees	$ 12,500	$ 15,000						$ 15,000			$ 7,500	$ 7,500		$ 12,500	$ 12,500	$ 7,500	$ 25,000
Inventory				$ 10,000									$ 20,000					$ 100,000	$ 130,000
Original issue discount							$ 5,556
Exchange of convertible notes payable							$ 50,000
Subsequent Event [Member] | Convertible Note Payable [Member] | Detachable Warrant [Member]
Warrants, term			5 years	5 years		5 years	5 years
Warrants to purchase of common stock shares			20,000	30,000		20,000	15,000
Stock, price per share			$ 5	$ 5		$ 5	$ 5
Subsequent Event [Member] | Convertible Note Payable Two [Member]
Debt instrument principal amount																					54,348
Subsequent Event [Member] | Convertible Note Payable Three [Member]
Debt instrument principal amount																					27,174
Subsequent Event [Member] | Convertible Note Payable Four [Member]
Debt instrument principal amount																					27,174
Subsequent Event [Member] | Convertible Note Payable Five [Member]
Debt instrument principal amount																					108,696
Subsequent Event [Member] | Convertible Note Payable Six [Member]
Debt instrument principal amount																					27,174
Subsequent Event [Member] | Convertible Note Payable Seven [Member]
Debt instrument principal amount																					16,304
Subsequent Event [Member] | Convertible Note Payable Eight [Member]
Debt instrument principal amount																					10,870
Subsequent Event [Member] | Convertible Note Payable Nine [Member]
Debt instrument principal amount																					52,632
Subsequent Event [Member] | Convertible Note Payable Ten [Member]
Debt instrument principal amount																					25,000
Subsequent Event [Member] | Convertible Note Payable Eleven [Member]
Debt instrument principal amount																					25,000
Subsequent Event [Member] | Convertible Note Payable Twelve [Member]
Debt instrument principal amount																					108,696
Subsequent Event [Member] | Convertible Note Payable Thirteen [Member]
Debt instrument principal amount																					60,000
Subsequent Event [Member] | Convertible Note Payable Fourteen [Member]
Debt instrument principal amount																					20,000
Subsequent Event [Member] | Convertible Note Payable Fifteen [Member]
Debt instrument principal amount																					$ 55,556
Subsequent Event [Member] | Convertible Note Payable One [Member]
Extension fees						$ 12,500
Series A Preferred Stock [Member] | Subsequent Event [Member]
Stock issued during period shares									2,000
Aggregate purchase price of shares									$ 50,000